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ABSTRACT 
 
Over the past decade, the illicit drug market has experienced an 
explosion of designer drugs being produced by clandestine laboratories that 
include modifications of illicit drugs that dominated drug markets for long 
periods of time (e.g. cathinones and MDMA). These designer drugs, which are 
commonly known as “legal highs”, are popular due to that fact that they are 
legally obtainable and not currently controlled. Examples of these include the 
phenylalkylamine analogues 5-iodo-2-aminoindane (5-IAI) and 5, 6-
methylenedixoy-2-amonindane (MDAI), which have similar biological effects to 
MDMA. In spite of the unknown risk factors associated with these substances, 
it is believed that “legal highs” continue to have high levels of interest among 
recreational users. As such, the potential for abuse is high, and 5-IAI and MDAI 
are under consideration in numerous jurisdictions for regulation.   
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Many of these novel compounds have never been analyzed previously 
within a forensic setting. The chemical and physical properties of 5-IAI and 
MDAI are not fully understood. As a result, the analytical analysis of “legal 
highs” can be challenging. Color test kits provide a quick screening method for 
law enforcement officials looking to presumptively identify a substance in the 
field. The difficulty with this form of analysis is that most of the active 
ingredients present in “legal highs” are not detected by standard presumptive 
tests, or the results when the tests are used are ambiguous. Gas 
chromatography-mass spectrometry (GC-MS) is one of the most utilized 
analytical instruments in forensic laboratories for the identification of drugs of 
abuse. However, due to the rapid development and commercialization of “legal 
highs,” the limited availability of certified reference standards and mass 
spectral data make the confirmatory analysis of “legal highs” challenging. 
The primary aims of this research were two-fold. The first was to evaluate 
selected commercially available Narcotics Analysis Reagent Kits (NARK® II) and 
color reagent formulations recommended by the National Institute of Justice 
(Color Tests Reagents/ Kits for Preliminary Identification of Drugs of Abuse) to 
determine if the phenylalkylamine analogues 5-IAI and MDAI generate a color 
development. If a color was generated using a particular reagent, further testing 
was conducted to establish if the observed color would be detectable in the 
presence of various adulterants. The second aim of this research was to develop 
a rapid GC-MS method for the detection of 5-IAI and MDAI in contrived multi-
component mixtures of selected adulterants.   
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Standard color tests provided consistent results for 5-IAI and MDAI pure 
samples as well as mixtures with adulterants. 5-IAI produced a light brown 
color with both the Marquis and the methylenedioxypyrovalerone (MDPV) color 
reagent tests. The Mandelin reagent from the NARK® II test kit produced a 
greenish brown color and a light green color with the In-House preparations of 
the same reagent when tested with MDAI. Confirmatory analysis was performed 
using GC-MS with a temperature gradient. The analysis was performed on a 
non- polar (5% phenyl) methylpolysiloxane column with a total run time of 10 
minutes. 5-IAI and MDAI were chromatographically separated and 
distinguishable from various adulterants based on retention time and mass to 
charge ratio.  
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1. Introduction  
 
1.1 An Introduction to “Legal Highs”  
 
Historically, “legal highs” or “herbal highs” are terms that refer to novel and 
emergent psychoactive substances that are blends of psychoactive plants or 
fungi that could be smoked or ingested to induce dissociative effects and 
hallucinations (1, 2). In the more recent years, these terms have been widened 
to include a rapidly growing range of synthetic designer drugs that have been 
grouped under the “legal high” terminology. The term “legal high” carries the 
perception of acceptability and safety. The compounds that are marketed to be 
the active ingredients in the “legal high” products are usually not controlled or 
regulated in many countries. A number of these compounds have not been 
subjected to specialized toxicological studies to determine the psychoactive 
potency or lethal dosages. Casual users of new substances of abuse are 
generally unaware of the purity and the ratios of the active ingredients (3). 
 Blindly experimenting with “legal highs,” recreational drug users tempt fate 
without the knowledge of the effects of the drug’s active ingredients on the 
human body. Classes of compounds that are considered to be under the 
umbrella of the “legal high” group include, but are not limited to, synthetic 
cannabinoids, such as JWH-122, which is a potent hallucinogen that mimics 
the active ingredient tetrahydrocannabinol (THC) in marijuana. Another 
example would be amphetamines, which includes stimulant analogues such as 
α-methyltryptamine (αMT).  
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The United Nations Office of Drugs and Crime (UNODC) postulated that new 
psychoactive substances are distributed to the illicit drug market because of 
several factors. The first and second factors address similar ideas in which 
different chemicals and precursors are used to elude established laws and 
regulations. The third factor is that there is a continual stream of supply and 
demand (4). This is based on the current substances availability on the illicit 
drug market. New substances are introduced to account for diminishing 
supplies and are synthesized to satisfy the demand by the user (4). 
In the past decade, “legal highs” have made a significant surge in the 
European illicit drug market, especially in the United Kingdom (UK). The trends 
on the availability of emerging “legal highs” are tracked by the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA). The EMCDDA is a 
program that monitors unregulated psychoactive products through a series of 
‘Snapshots’ that function as rapid assessments of the online availability of 
substances, during a limited time window (5).  
The EMCDDA ‘Snapshots’ of January and July 2011 in Figure 1 depicts over 
10 countries that have online shops that provide “legal highs” available for 
purchase. The information gathered by the EMCDDA identified 631 online 
shops in July 2011, which doubled the amount of online stores available in 
comparison to January 2011 at 314 online shops. In their study, it was 
identified that approximately one third of the online shops (197 of 631) had 
originated from the United States (US) and one fifth (121of 631) were based in 
the UK. It is important to keep in mind that it is still unclear as to the actual 
size of the Internet market as a source of “legal highs”, although this 
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information does provide insight on the growing interests of these compounds 
for their psychoactive properties.  
 
 
Figure1. 2011 Snapshot of the countries of origin for online shops selling and 
shipping other ‘legal highs’ or novel psychoactive substances (5).  
 
Countries that have a prominent illicit drug culture are at the biggest risk 
for emerging “legal highs”. The large number of new substances that enter the 
drug market worldwide poses a threat to public health and presents a challenge 
to law enforcement systems. Countries have attempted to address the 
regulation problems of these products through the application of ‘emergency 
scheduling’ mechanisms. Some countries employed the application of 
‘emergency generic scheduling mechanisms’ that automatically include any 
analogue substance under regulation. It can be difficult for many legal systems 
to implement new ‘generic scheduling mechanisms’, therefore countries that 
face that issue opted to regulate a number of these new substances under the 
4 
 
control of legislation that is similar to the UK’s ‘Medicines Act’. This act 
generally requires medicinal products to be properly tested before they can be 
sold to the generic public (4).   
The UK has seen an explosion in the number of novel compounds (6, 7) that 
are appearing on the Internet which are advertised to share similar structures 
and or common functional groups with highly abused controlled substances. 
The UK’s drug abuse legislation, the Misuse of Drug Act of 1971, did not control 
the novel synthetic modifications of highly controlled substances. This allowed 
the use of these synthetic compounds to go unpunished and contributed to 
their popularity. The lack of specificity to address new substances of abuse in 
the Misuse of Drug Act of 1971 meant that many of the “legal high” substances 
could be obtained without a license and be sold to consumers. This was 
facilitated by online shops with little to no repercussions to the distributor(s).  
In the past decade, the UK’s most prevalent classes of ‘legal highs’ that were 
available included synthetic phenylethylamines, amphetamines and cathinone 
classes. Within these classes, the most commonly known and abused synthetic 
“legal highs” included; 4-methylmethcathinone (mephedrone), 3, 4-methylene-
dioxy-N-methylcathinone (methylone), 3, 4-methylenedioxypryovalerone 
(MDPV), N-methylcathinone (methcathinone), 4-methyl-N-ethylcathinone (4-
MEC), and  β-keto-N- methyl benzodioxole propylamine (butylone). These 
substances among others were dubbed first generation “legal highs.” Later, 
there were second generation “legal highs” due to the legislation of first 
generation illicit substances. Both generations are marketed to produce 
distinctive and desired psychopharmacologic effects similar to highly regulated 
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controlled substances such as cathinone or 3, 4-methylenedioxy-N-
methamphetamine (MDMA). Novel compounds in “legal highs” can have similar 
toxicity and desired effect as classically controlled drugs of abuse. Without 
rigorous drug discrimination and behavioral studies of newly emergent 
substances of abuse, the pharmacokinetics, psychopharmacological effects and 
toxicity of these substances in humans are merely theorized.  
 The National Forensic Laboratory Information System (NFLIS), a program 
that systematically collects drug identification results, had gathered 
information on synthetic cannabinoids and synthetic cathinones from drug 
cases submitted to and analyzed by federal, state, and local laboratories. The 
NFLIS special report on synthetic cannabinoids and synthetic cathinones stated 
that in 2010 there were 628 reports of synthetic cathinone exposures from 27 
states. This was a significant increase in exposures  when compared to the  34 
reports from eight states in 2009 (8).  
The NFLIS special report also presented data gathered on “exposures” to 
synthetic cannabinoids and synthetic cathinones reported to the American 
Association of Poison Control Centers (AAPCC) from January 2010 through to 
July 2011. The APPCC noted a steady increase in calls related to synthetic 
cathinone “exposures” in each month since mid-July 2010 and then increased 
nearly tenfold that amount  from 2010 through the first six months of 2011 
(303 vs. 3,497) (8). This report provides some insight on the growing popularity 
amongst drug users to experiment with “legal highs”. Relying solely on existing 
drug abuse legislation may not be enough to control the supply of these new 
compounds from entering the illicit drug market. An intelligent and pragmatic 
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approach to recreational drug use needs to be sought out urgently to maintain 
public health and safety.  
In response to the rapidly increased usage and unknown documented health 
risks associated with ‘legal highs’, the UK implemented legislation that would 
control the usage of specific types of “legal highs” including mephedrone and 
other synthetic cathinone derivatives. The United Kingdom Advisory Council on 
the Misuse of Drugs had placed mephedrone and other cathinone derivatives 
under the classification as Class B, Schedule I on April 16 2010 (9-11). The US 
followed suit with the regulation of various synthetic novel compounds that 
were under the guise of a “legal high”.  
In the US, distributors of “legal highs” avoided legislation from the Title 
United States Code (USC) Controlled Substance Act (CSA); Section 813. Treatment 
of Controlled Substances Analogues [21USC813] (12), which states that a 
controlled substance analogue intended for human consumption shall be 
treated as a controlled substance in Schedule I. “Legal highs” are frequently 
advertised as ‘air fresheners’, ‘herbal incenses’, ‘research chemicals’, ‘bath 
salts’, ‘plant food’, or ‘plant fertilizers’ to be sold for purposes other than human 
consumption over the Internet (6, 13). Illicit drug distributors use compounds 
that are legal to possess and sell to create these products, so they can avoid 
established regulations and testing regimens (13).  
The DEA and Department of Justice (DOJ) issued a notice of intent [21 Code 
of Federal Regulations (CFR) Part 1308; Docket No. DEA-357; 21 U.S C. 811(h)] to 
temporarily schedule three synthetic cathinones under the CSA pursuant to the 
temporary placement of the following synthetic cathinones into Schedule I of 
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the CSA on September 8, 2011 (14). The substances were mephedrone, 
methylone, and 3, 4-methylenedioxypyrovalerone (MDPV). The Drug 
Enforcement Agency’s (DEA) intent to declare mephedrone, methylone, and 
MDPV as temporary Schedule I compounds had mitigating circumstances. 
There was a lack of scientific data available at the time concerning synthetic 
cathinones and it was determined that these substances posed an imminent 
threat to public safety. These compounds were found to have an elevated level 
of abuse across the United States. The increased usage of these compounds led 
to 37 states implementing statewide regulations on these synthetic cathinones. 
It was believed that these substances were abused as alternative to illicit 
stimulants such as 3, 4-methylenedioxy-N-methylamphetamine (MDMA) and 
cocaine because of their similar psychoactive properties (15). In addition, the 
public health consequences of these compounds were documented through 
reports by federal, state and poison control agencies like the APPCC, in which 
the use of synthetic cathinones resulted in emergency room visits and deaths.  
The final order to regulate these synthetic cathinones was made on October 
21, 2011 under the provisions of the 21 U.S.C. 811(h) (15). This statue not only 
regulated these synthetic cathinones but their isomers, salts and salts of 
isomers (16). These regulations were intended to reduce and or eliminate the 
accessibility of these synthetic cathinone products from purchase over the 
Internet. It could be argued the that reclassification of mephedrone and other 
forms of “legal highs” left a gap for a new wave of second generation substances 
to enter the illicit drug market as potential replacements (11, 17). In response 
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to the ban of first generation “legal highs”, a number of second generation “legal 
highs” were marketed as analogues of the substances that had just been placed 
under legal control. These second generation “legal highs” presumably gave 
similar or new psychotropic experiences to that of the first generation “legal 
highs” (5, 14). An alternative product that has been promoted on the Internet 
included a group of compounds known as aminoindanes (2-aminoindane, 2-AI) 
and their structural derivatives 5, 6-methylenedioxy-2-aminoindane (MDAI,) 
and 5-Iodo-2-aminoindane (5-IAI) 5, 6-methylenedioxy-N-methyl-2-aminoindane 
(MDMAI) and 5-methoxy-6-methyl-2-aminoindane (MMAI).  
Suppliers of “legal highs” continually utilize legal loopholes in order to 
market and facilitate the purchase of emerging second generation “legal highs” 
(e.g. aminoindane group of compounds) as a substitute for banned first 
generation “legal highs”. Figure 2 was generated by Google Insights to search 
the number of keyword searches for MDAI and 5-IAI between 2006 and April 
2012. The highest peaks for MDAI and 5-IAI indicated that these compounds 
were at the highest interest approximately near May 2010. This coincided to the 
same period that UK’s governing bodies passed legislation to regulate 
mephedrone and other synthetic cathinones. This illustrates the propensity of 
drug users to obtain new emerging psychoactive drugs that are unregulated.  
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Figure 2. Keyword searches for 5, 6-methylenedioxy-2-aminoindane (MDAI) (blue) 
and 5-iodo-2-amoinoindane (5-IAI) (red) on Google from 2006-2012 (generated using 
Google Insights for Search). The number 100 represents the peak volume search 
 
 
The majority of emerging second generation “legal highs” fall outside the 
definition of a medicinal product under the Medicines Act of 1971 (17) in the UK 
and under the treatment of a controlled substance analogue under Title 21 
United States Code(USC) Controlled Substances Act(CSA);813 (18). This indicates 
that 2-aminoindane derivatives were not regulated as a ‘controlled substance’ in 
the UK and US, which increases their likelihood of potential usage. If these 
compounds enjoy the same popularity as their first generation predecessors 
then it is possible that MDAI and 5-IAI will become part of a new wave of “legal 
highs” within the drug culture.  
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1.2 Chemistry of MDAI and 5-IAI 
MDAI and 5-IAI were synthesized in the early 1990s by Dr. David Nichols 
and were later grouped under the drug classification of entactogens, a sub-
category of stimulants and hallucinogens (19, 20). MDAI is considered to be a 
substituted analogue of the illicit drug MDMA (21) . It is believed that the 
dioxole ring on the MDAI structure is responsible for the interaction between 
dopamine (DA) and serotonin transport systems (17, 22). This would indicate 
that MDAI and MDMA share similar pharmacological profiles. 5-IAI is 
considered an analogue of para-iodoamphetamine (PIA) (20, 23). The α-methyl 
group of PIA is bound to the aromatic nucleus to form an indane ring structure 
(22, 24). Through drug discovery experimentations, Johnson et al. published 
that these compounds were selective, potent and non-neurotoxic releasing 
agents of serotonin, norepinephrine and DA. This was in addition to reporting 
that 5-IAI and MDAI are re-uptake inhibitors of the 5-hydroxytyptamine (5-HT) 
and 5-hydroxyindoleacetic acid (5-HIAA) neurotransmitters (21, 25, 26). Figure 
3 depicts the structures of 2-AI, MDAI, and 5-IAI; it also displays a comparison 
of the structural similarities between Methamphetamine, MDA and MDMA. 
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Figure 3. Structure of amphetamines and aminoindanes, the structures of d-
methamphetamine and 3, 4-methylenedioxymethamphetamine (MDA) in 
comparison to 2-aminoindane (2-AI) to show their similarity to; 3, 4-
methylenedioxymethamphetamine (MDMA), 5, 6-methylenedioxy-2-aminoindane 
(MDAI) (5), and 5-iodo-2-aminoidane (5-IAI) 
 
There is limited published data on the chemical characteristics of 5-IAI and 
MDAI. The majority of the interest for these substances had been established in 
the studying of the pharmacological effects and evaluation of their 
neurotoxicity. A recent review of aminoindanes indicated some of the challenges 
encountered in identifying these emerging “legal highs” as well as addressing 
the need for characterization profiles of these compounds for comparative 
purposes (1, 24). John F. Casale and Patrick A. Hays synthesized and 
characterized 5, 6-MDAI and 4, 5- MDAI in 2011. Casale and Hays conducted 
this study to determine structural information of the final product, 
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intermediates and any impurities. Their goal was to provide assistance to 
forensic chemists that may encounter such compounds in casework (27). 
Chromatographic data was obtained using Gas Chromatography-Mass 
Spectrometry (GC-MS). The structures were determined using hydrogen (1H), 
carbon-13 (13C), and 2-dimensional (2D) Nuclear Magnetic Resonance (NMR) 
spectroscopy. Fourier Transform Infrared (FTIR) spectroscopy was used to 
differentiate the positional isomers and their intermediates. Casale and Hays 
also synthesized four and five-iodo-2-aminoindane in 2012 (24) to derive 
structural information about these substances in the same manner as the 
MDAI study. 
MDAI and 5-IAI were named and classified by the Chemical Abstract Service 
(CAS) as 6, 7-dihydro-5H-cyclopenta[f] [1, 3] benzodioxol-6-amine and 5-iodo-2, 
3-dihydro-1H-inden-2-amine, respectively. The CAS# for MDAI is 132741-81-2 
and the molecular formula is C10H11NO2 with a molecular weight of 177.199 
g/mol. The CAS# for 5-IAI is 132367-76-1 and the molecular formula is C9H10IN 
with a molecular weight of 259.087 g/mol. 
In low doses, MDAI and other amphetamine type stimulants (ATS) such as 
5-IAI are hallucinogens and can cause psychomotor stimulations in higher 
doses (17). According to MDAI users, its effects are similar to those of 
MDMA/ecstasy. Being an entactogenic drug, MDAI can produce euphoria, 
empathy, intensification of sensory experiences and entheogenic experiences 
(17, 20). 
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1.3 History and Pharmacology of MDAI and 5-IAI 
In 1973, Everett Solomon and Joseph Sam assessed the bronchodilating 
and analgesic properties of 2-AI (28) , further research proved 2-AI to be a 
potent serotonin releaser for the 5-HT and 5-HIAA neurotransmitters. 5-HT is a 
neurotransmitter that is found within the central nervous system (CNS) that is 
associated with feelings of well-being and happiness. 5-HIAA is the primary 
metabolite of serotonin in the human body. 5-HIAA receptors are located in the 
frontal cortex, hippocampus, and striatum (a major input for the basil ganglia 
system) of the brain (25, 26) . 2-AI has also proved to be a serotonin re-uptake 
inhibitor (SRI) in which the mode of action is to block the serotonin transport 
system in the CNS. This causes an increased extracellular concentration of 
serotonin. This has a proportional relationship to the level of serotonergic 
neurotransmission (1). Solomon and Sam suspected that 2-AI was a cyclic 
analogue of amphetamine. It was not until the late 1970’s and early 1980’s 
where researchers recognized that 2-AI was a semi rigid -N-alkylated conger of 
β-phenethylamines, similar to amphetamine and methamphetamine (29, 30). 
 Researchers continued to synthesize and evaluate the behavioral effects 
and pharmacological properties of amphetamine analogues and analogues of 
other substituted phenylalkylamines, such as para-chloroamphetamine (PCA), 
3, 4- methylenedioxyamphetamine (MDA) and MDMA. MDA and MDMA are 
theorized to be the model compounds for the pharmacological effects that 
aminoindane compounds mimic. In 1986, Nichols et al. classified the commonly 
abused drugs MDA and MDMA, popularized in the nightclub scene during the 
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1970’s, as entactogens. This is a term that is used to classify a series of drugs 
closely related in structure and share similar biological potency in humans that 
do not fit the definitions of hallucinogens or stimulants (31). Entactogens are 
compounds that cause the release of neurotransmitter serotonin in the brain 
which can cause distinctive emotional and social effects, hence the literal 
meaning of the word “producing a touching within” (19, 31). MDA does not 
produce profound sensory disruption or hallucinations in the traditional sense. 
MDA has been reported by users to be a promoter of self-knowledge and the 
concept of self, along with the power to enhance empathy and the desire to 
communicate, earning it the name “Love Drug” (19, 31, 32). MDMA, the N-
methyl derivative of MDA is biologically active in similar ways to its parent 
compound. MDMA induces a state of reduced anxiety and lowered 
defensiveness that made it attractive to therapists wishing to speed up the 
therapeutic process during the drugs initial pharmaceutical testing stages (19, 
20).  
 Through a ten-year span of studies of MDA and MDMA among other 
similar psychoactive phenylalkylamines, it was shown that these compounds 
produce serotonin neurotoxicity. Serotonin neurotoxicity refers to the 
destruction of serotonin neuronal terminals. MDMA was shown to lead to 
neuron degeneration in rodents and in non-human primates (22, 31, 33, 34). 
This finding is a major consideration that prevented possible clinical studies 
with MDMA in the US and was a major concern for public health due to the 
widespread abuse of this substance (20). As Nichols identified the serotonin 
properties of MDMA, work was carried out to identify molecules that had 
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similar serotonergic properties but lacked the serotonin neurotoxic effects. 
Kovar et al. summarized the neurological processes that occur with the CNS in 
the presence of any of the psychoactive entactogens. These findings are 
summarized in Table 1.  
 
Table 1. Neurological processes associated with entactogens on the 
Central Nervous System (19) 
Enhancement of neuronal serotonin release from the cytoplasmic 
stores 
 
Blocking of the serotonin re-uptake sites and thus prevention of 
serotonin re-uptake 
 
Antagonistic effect at the alpha-2-heteroreceptor (producing further 
serotonin release) 
 
Inhibition of the tryptophan hydroxylase (enzyme involved with the 
synthesis of serotonin 
 
 
 
The acute pharmacological effects of entactogens result in an excess of 
serotonin in the synaptic cleft. The intrinsic details of this specific drug 
classification are further described in Dr. Nichols’ publication “Differences 
between the mechanism of action for MDMA, MBDB, and the Classic 
Hallucinogens. Identification of a New Therapeutic Class: Entactogens” (31). 
Schmidt et al. characterized that entactogens not only block serotonergic re-
uptake processes, but also noradrenergic and dopaminergic re-uptake 
processes , ultimately causing additional stimulating effects and interactions 
with the CNS (19).  
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The illicit drug market has experienced and undergone very significant 
changes in the late 1990s (32). During this time, spanning into the early 2000s, 
there was an explosion of designer drugs being produced by clandestine 
laboratories that included structural modifications from traditional illicit drugs 
that dominated the illicit markets for such long periods. This included 
commonly abused drugs such as heroin, cocaine, marijuana, and ecstasy 
(MDMA). These compounds are highly sought after due to the characteristic 
“hallucinogenic and stimulating dissociative” effects similar to that of traditional 
illicit drugs.  
Phenylalkylamines are one of the largest classes of compounds that can 
be chemically altered or modified to circumvent classification under established 
narcotics acts. This includes a wide spectrum of structures that ranged from 
tryptamines, piperazines, synthetic cathinones, and substituted 
phenylethylamines. Many of these clandestinely produced designer drugs 
originated from the works of therapeutic researchers carried out in academic 
laboratories and scientific research facilities worldwide. The majority of these 
researchers intended for their work to provide medicines or therapeutic 
treatment for ill people. It was not uncommon for many unknown amateur 
chemists to follow publications, notes, follow online forums or send letters/ 
emails of correspondence to the published authors inquiring about the 
synthetic process or the human effects of the synthesized compounds 
referenced in the scientific publications (35, 36). 
MDAI was first synthesized at Purdue University (USA) by Dr. David 
Nichols and his team during the 1990s (21). MDAI was discovered accidently 
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during the process of researching what modulation of serotonin functions in the 
CNS might have on a variety of therapeutic applications, which included 
experimentation with MDA, MDMA and other related compounds (17, 20). Dr. 
David Nichols was also credited with synthesizing 5-IAI in the 1990s, while 
researching the pharmacological properties of para-iodoamphetamine (PIA) 
analogues (23). Dr. Nichols considered these compounds to be analogues of 
MDA and MDMA (21). Based on their structural similarity and mode of action, 
Dr. Nichols classified 5-IAI and MDAI as entactogens. Consequently, Kovar 
described that the synthesized MDAI compound “is slightly more potent than 2, 
5-dimethoxy-4- bromoamphetamine (DOB)” and nearly 200 times the potency of 
mescaline (19). 
Johnson et al. discovered that the mode of action of MDAI to be that of a 
SRI and a fairly potent releaser of 5-HIAA and 5-HT neurotransmitters (19, 20, 
25, 26). MDAI was found to give full substitution in drug discrimination assays 
using MDMA as the training drug in rodents (20). By definition, drug 
discrimination assays are procedures that allow a subjective drug effect to 
direct choice behavior. In this paradigm, animals are used and taught to 
perform a particular action under the influence of one drug and another action 
or no action when another drug or no drug is administered (e.g. turn left vs. 
turn right vs. no response). The reaction of the animal while under the use of 
the administered drug serves as a discriminative baseline for a particular 
response. This type of drug model is used to determine whether the 
pharmacological properties of a new drug are similar to an established drug 
(37).  
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 It was also found that MDAI, to a lesser extent, inhibited the uptake of 
DA and NE (25, 26). This is also true for 5-IAI, although the effects of 5-IAI 
through drug discrimination studies have been reported to be less prevalent 
than MDAI. In addition to the neurological properties of 5-IAI and MDAI, 
researchers continued to study derivatives of 2-AI because of their lack of 
serotonin neurotoxicity (20). This attribute of MDAI, 5-IAI and other 2-AI 
derivatives was essential to researchers who were attempting to use these 
compounds for therapeutic applications in anxiety, depression, and panic 
disorders. The research established using 5-IAI and MDAI indicated that 
compounds could be developed that possessed MDMA-like effects in behavioral 
studies but lacked the serotonin neurotoxicity associated with administration of 
MDA or MDMA (20, 21, 23). 
 
 
 
1.4 Challenges with the Analysis of “Legal Highs” 
 
The emergence of synthetically derived drugs classified as “legal high” 
compounds have presented a clear and obvious problem in today’s society. The 
unprecedented challenges that government agencies face in order to maintain 
control of emerging drug trends is a never-ending routine. The lack of 
documented knowledge of legal highs’ effects on humans, the psychoactive 
potency and the lethal dosage ranges provide reasons why these compounds 
need to be properly studied. The scientific study of these compounds would 
provide an understanding of their effects, toxicity, and allude to any possible 
beneficial medicinal or scientific advancement. If the conclusions of such a 
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study prove that these drugs have viable medicinal or scientific purposes then 
appropriate classification and regulation is warranted.  
In the process of implementing these policies there are numerous 
challenges encountered along the route to understanding “legal highs” and their 
effects on society. Challenges are encountered in the analytical analysis of “legal 
highs” as well as the legal system. Due to the rapid development of “legal highs” 
the availability of certified reference standards (including major metabolites of 
identified drugs) are limited (1, 38). Analytical chemists largely rely on 
spectroscopy to characterize materials obtained in illegal drug seizures. 
Generally, presumptive spot tests are performed on seized illicit drugs or 
immunoassay tests are performed on biological materials. There is some 
difficulty associated with these methods of analysis when applying them to the 
identification of “legal highs”. These compounds can go undetected by standard 
means of presumptive drug spot tests or screening tests or their results are 
ambiguous. This is a result of many of these “legal high” compound’s active 
ingredients are not susceptible to these forms of analysis (38).  
Gas Chromatography – Electron Impact/ Mass Spectrometry (GC-EI/MS) 
is the most commonly used analytical technique to identify and characterize 
new compounds. Chromatograms and mass spectral data are utilized in the 
identification process of new compounds. GC-MS cannot provide an absolute 
elucidation of unknown structures without the use of certified reference 
standards or MS databases that have already characterized these compounds 
for comparison purposes. The lack of accessible mass spectral data for “legal 
high” substances through commercial and dedicated MS databases (e.g. 
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National Institute of Standards and Technology (NIST) and 
Maurer/Pfleger/Weber) can hinder the confirmatory analysis process (38). They 
are not able to positively characterize and update their databases at the same 
rate new designer drugs are appearing on the illicit drug market. This forces 
laboratories to synthesize these substances for the purpose of obtaining a broad 
understanding of their analytical profiles, which can take up valuable time and 
resources.  
Due to difficulties with this approach, many users of “legal highs” elude 
detection through drug testing. The fact is that many the drugs are in a 
figurative window of invisibility as analytical and forensic laboratories develop 
new methods of detection for the increasing influx of these compounds (7). It is 
important for drug analysts to keep abreast with current drug trends, drug 
control policies, be aware of publications relating to new substances and more 
importantly to have an international collaborative effort amongst laboratories to 
assist in the rapid identification of new drugs of abuse (36, 38). 
 When a drug is made illegal, it is done so to limit the supply of the drug 
and to minimize harm to the public. Nevertheless, distributors of these 
products  avoid legal ramifications by claiming that the ‘air fresheners’, ‘herbal 
incenses’ or ‘research chemicals’ that they sell are ‘not intended for human 
consumption’ (7). This makes it very difficult for the prosecution to have any 
legal precedence to bring up charges of drug violations. The core of the legal 
difficulties regarding the prosecution of “legal highs” is due to the development 
of rapid technologies and cheaper organic synthesis processes (39). It is 
expected that new compounds will continue to emerge, regardless of any 
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sanctions, laws or other regulations. Contemporary chemistry will continue to 
provide a means for new substances to appear under a new name that have 
been slightly modified with similar effects to their predecessors (39).  
 
1.5 Adulterants  
Illicit drugs typically contain other substances in addition to the purported 
drug that can have serious adverse health consequences or even cause 
premature death (40). The substances that modify the composition of illicit 
drugs are known as cutting agents. Many factors affect the degree of 
adulteration within the illicit drug market. The supply, demand and control of 
illicit drugs have an impact on the degree of adulteration in a “street quality” 
drug sample.  
Generally, drug manufacturers add substances to increase bulk, dilute, 
complement, or facilitate the administration of the drug (40). Cutting agents are 
broken down into two categories, adulterants and diluents. Adulterants by 
definition are pharmacologically active ingredients that mimic the biological 
effects of the drug of abuse. Drug dealers utilize adulterants in an effort to 
provide the false perception of a higher quality drug sample to the user (41, 42). 
Diluents are pharmacologically inert ingredients that do not mimic the 
biological effects of the active ingredient (41, 42). Diluents are added to bulk up 
the drug composition and decrease the amount of active ingredient (41). While 
these terms have slightly different connotations, they are used interchangeably 
within the scientific and law enforcement communities. For this work, the term 
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adulterant will be used for all mixtures containing target analyte and any 
additional adulterating compound.  
There have been numerous detailed studies where adulterants have been 
reported in illicit drugs. Articles published by authors such as Siegel et al. (43) 
and Renfroe et al. (44) have detailed the adulterant composition and purity of 
MDMA (ecstasy) tablets in the mid 1980’s. Pills marketed as ecstasy may 
contain a wide variety of compounds. The trends observed in published articles 
can provide insight on the likely cutting agents that could be anticipated to be 
present within synthetic designer drug tablets or powders. According to Siegel, 
ecstasy tablets were reported to contain a wide range of adulterants including 
ephedrine, phenylpropanolamine, procaine and niacinamide (43). There are a 
number of other active and inactive ingredients that could be added to ecstasy 
tablets/powders during the drug production process for various enhancement 
or bulking purposes. The most prevalent adulterants that have been identified 
in the most recent decades for the production of ecstasy have included caffeine, 
dextromethorphan and paracetamol in varying percentages (41). It has also 
been reported that analogues of MDMA have been identified, MDA and or 3, 4-
methylenedioxy-N-ethylamphetamine (MDEA or MDE), within seized tablets 
which would exacerbate the psychoactive properties of MDMA (41).  
It can prove beneficial to determine extent of the seized illicit drugs’ 
adulteration. This would provide supplementary information when identifying 
the main component of the illicit drug sample. The majority of adulterants seen 
in the illicit drug market are readily available and legal to obtain and possess. 
These factors are attractive to drug manufacturers in clandestine laboratories 
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because they can easily use the adulterants to enhance, mimic or add bulk to 
their illicit product. While published works provide insight on shifting drug 
trends in various regions around the world, the lack of standardized forensic 
analysis and report practices to determine the extent of adulteration highlights 
an area of seized drugs analysis that could be improved for forensic casework. 
Forensic analysis is undertaken after a drug seizure to provide evidence for law 
enforcement, the judicial system or medical information on adverse health 
effects in an individual or a group of individuals (40). Implementing a database 
that would require laboratories to report and input information regarding the 
overall composition of the drug and degree of adulteration would be 
instrumental in monitoring, comparing and localizing adulteration practices 
over a period of time or particular regions of a country. Despite the lack of 
national or international standardized guidelines for the analysis and reporting 
of adulteration, profiling data is being used to categorize drug samples into 
similar groups to provide investigative information such as learning that 
samples have a common origin. This type of profiling is referred to as “Chemical 
Fingerprinting”. This entails profiling a drug sample’s composition beyond 
simple identification and quantitation of the controlled substance(s) present 
within a sample (45). 
A prime example of such a process is the Early Warning System (EWS). The 
EWS is an international database that was established by UNODC. The EWS is 
used to identify new emerging synthetic drugs, emerging drug trends, new 
product combinations, controlled and non-controlled precursors, and common 
adulterants used in illicit drug manufacture (40, 46). The European-EWS 
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identified over 40 new substances in 2010, which was a significant increase to 
the 24 emerging substances that were identified in 2009 (4). These emerging 
drugs included piperazines, phenylethylamines, synthetic cathinones and 
synthetic cannabinoids.  
UNODC depicted the EWS as a good model for sharing intelligence across 
Europe and international agencies. There is a need to understand the intrinsic 
details of the drug market and that includes proper documentation and 
reporting of adulterants in illicit drugs. The continuing development of 
searchable databases such as the EWS can be an important tool in tracking 
existing and emergent drugs as well as identifying the “chemical fingerprint” of 
a substance within a given geographical regions. 
2. Forensic Analysis of “Legal Highs” 
 
2.1 Colorimetric Tests 
 
It is known that colorimetric tests have been modified to adhere to the 
needs of analytical chemists in a wide variety of fields and disciplines. Chemical 
color tests that are used for the preliminary identification of illicit drugs are 
known to be halo-chromic in nature (47). This describes a chemical reaction 
that transforms a colorless compound into a colored compound as a result of 
either an acid/base addition or ion formation.  
The color developments that are observed are not specific to one 
compound but are produced by unrelated compounds that share similar 
functional groups or other points of structural similarity. The purposes of such 
tests are to determine the possible presence or absence of a substance in a 
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sample. Despite the shortcomings of color spot tests, such as false positives and 
negatives, unexpected colors or subjectivity of color interpretation, they are still 
useful in answering preliminary questions quickly in fieldwork and by analysts 
within a laboratory setting (48).  
Since MDAI and 5-IAI both have an amine moiety with an aromatic 
structure, specific reagents were chosen which react with these groups. In some 
instances, a methylenedioxy moiety is incorporated into the molecular 
structure. In an effort to identify these compounds, it is an appropriate 
analytical strategy to use colorimetric reagents that are known to react with 
either of these functional groups. This includes but is not limited to Marquis 
reagent, Mandelin reagent or Froehde reagents. These are just a few of the tests 
that are used for this type of analysis. These reagents are not highly specific in 
that they could react with any compound that share similar chemistry. 
However, colorimetric reagents can serve as a good preliminary indicator of 
functional group(s) which warrant further testing (49).  
Narcotics Analysis Reagent Kits (NARK®) that are generally used for the 
analysis of substances containing methylenedioxyphenyl groups are based on 
the Marquis (sulfuric acid/formaldehyde) reagent tests that result in a 
purple/black or blue/black color development. The Mecke (sulfuric 
acid/selenious acid) reagent test has been used for the general identification of 
opium alkaloids but also as an indicator of aromatic containing compounds, 
such as DOB hydrochloric acid (HCl) and MDA HCl, and produces a dark brown 
and dark bluish green color development, respectively. The solvent chosen, the 
concentration of solute, or the presence of adulterants can affect the 
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subjectivity of the color interpretation perceived by the administrating analyst 
(49).  
 Johns et al. reported that a multitude of reactions, such as esterification, 
oxidation, dehydration, and hydrolysis are fostered by sulfuric acid. For this 
reason, his team decided to incorporate Marquis, Mecke, Mandelin and Froehde 
reagents within their study on the effects of colorimetric reagents on illicit 
substances (49). These reagents were considered and included within this study 
in an attempt to observe the behavior of these aminoindane compounds in the 
presence of colorimetric reagents.  
 
2.2 Gas Chromatography - Mass Spectrometry 
Gas Chromatography (GC) followed by Mass Spectrometry (MS) is one of 
the most basic analytical techniques used for qualitative and quantitative 
analysis of diverse psychoactive drugs in most forensic laboratories. GC 
consists of several components that are integral to the accurate separation and 
identification of compounds. These components include an injection port, a 
mobile phase (typically helium), temperature-regulated oven, a column with a 
selected stationary phase, a detection system, and a data system.  
GC enables separation of many compounds in a relatively short amount 
of time with the use of columns that are lined with a specifically selected 
polymer stationary phase. The columns are contained within a temperature-
regulated oven that can influence the degree of separation. The most commonly 
used GC column for the analysis of “legal highs” is a non-polar DB-5MS [(5%-
phenyl)-methylpolysiloxane] (38). This type of column enables good separation 
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efficiency of many structural isomers. Most active components of “legal highs” 
are typically subjected to this form of instrumental analysis and are 
characterized by GC due to the volatile properties of these compounds. 
Chromatographic separation of a compound in a multi-component solution is 
generally based on chemical composition, differential solubilities and time spent 
interacting between the mobile and stationary phases. As compounds of 
interest are separated by GC, they can then be subjected to one of many types 
of ionization modes, the discussion of which is beyond the scope of this thesis. 
The ionization technique used in this study was electron impact (EI). In this 
“hard” ionization method, a beam of energetic electrons is used to produce ionic 
products (50). Ionization and fragmentation of gas-phase analyte molecules is 
achieved by interactions with energetic electrons produced from the filament 
(45, 50, 51).  
EI – MS in unison with GC is one of the most common analytical 
techniques used to identify drugs of abuse. Characterization of compounds by 
EI is attributed to the interactions of energetic electrons with the target analyte 
to create fragmented species, as previously discussed. Any fragmentation ions 
of interest are generated from neutral molecules that have undergone the loss of 
an electron. This molecule is referred to as the molecular ion. The molecular ion 
provides valuable information in the mass spectrum. The fragmentation ions 
that are observed in the mass spectra are a result of the decomposition of the 
molecular ion (50, 51). 
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The fragmented ions relate specifically to the structure of the molecular 
ion and are separated by abundance of the ion(s) and mass to charge (m/z) in 
the mass analyzer portion of the instrument. The most readily used mass 
analyzer in drug analysis is a single quadrupole mass analyzer. A single 
quadrupole mass analyzer consists of four parallel rods that have a fixed direct 
current (DC) and alternating radio frequency (RF) potentials applied to them. 
The ions produced by the EI process are focused and passed through the 
middle of the quadrupole. The pathway of the ions depends on the electric fields 
so that the ions of a particular m/z will have a stable trajectory to the detector 
(52). Fragmented ions created through the EI process, within a given scan 
range, would reach the detector, be amplified and then mapped out based on 
m/z ratio and abundance. This information is represented in what it is 
commonly known as a mass spectrum. The complexity of fragmentation 
patterns has led mass spectra to be used as unique identifiers or “fingerprints” 
for identifying various analytes (53). There are specialized libraries such as the 
National Institute of Standards and Technology (NIST) Mass Spectral Library, 
Maurer/Pfleger/Weber MS Library, and Cayman Spectral Library that have 
accumulated spectra of organic compounds, synthesized compounds, poisons, 
drugs and their metabolites (38). Despite the fact that these libraries are made 
available to forensic laboratories, the process of identifying “legal highs” is 
limited due to the fact that most of the active ingredients used to manufacture 
potential substances of abuse have yet to be included in these specialized 
libraries. For the purposes of this thesis project, GC-EI/MS was used to 
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separate, detect and identify the various compounds present in the “legal high” 
samples and the adulterants present within the contrived mixtures.  
 
2.3 Proposed Scheme for the Analysis of 5-IAI and MDAI  
 As a direct result of the recreational usage and illicit drug market 
trends, forensic scientists and crime labs have found a need to identify the 
compounds present in “legal highs”. Sensible techniques for the analysis of 5-
IAI and MDAI and other “legal highs” need to be researched for the purposes of 
accurate characterization and possible quantification. The best solution for this 
would be to invest in techniques and instrumentation that are simple, relatively 
fast, low in maintenance, cost effective and whose result can be easily 
interpreted.  
Chemical spot tests meet all of these criteria with relative ease. An 
inherent quality that continues to drive the usage of such tests is that they are 
based on simple chemical reactions and can be visualized by the unaided eye. 
The same notion is applicable to NARK® II reagent test kits. NARK® II kits are 
commercially available products that can be purchased in bundled kits 
containing particular sets of tests or as separate individual test packets based 
on the needs of the consumer. These features make color reagent formulations 
and testing kits an ideal starting point for progressively identifying and 
designing tests for 5-IAI and MDAI. 
Confirmatory analysis would be the logical next step when developing an 
analytical scheme for the identification of any unknown substance. GC-MS, 
being one of the most widely used confirmatory techniques, can provide 
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confirmation of the presumptive tests that were performed in this study. The 
progressive analysis of 5-IAI and MDAI lead to several questions to be 
answered, namely: 
1. Does either 5-IAI or MDAI cause an unexpected color change to 
occur that might be unique to either of their molecular 
structures? 
2. Does either 5-IAI or MDAI cause a color change that would lead 
to further testing? 
3. Would the generated color, if any, of 5-IAI or MDAI be visually 
detected in the presence of common adulterants? 
4. Are these compounds capable of being detected and 
quantitated in a contrived multi-component mixture comprised 
of selected adulterants? 
These are some questions that will be used to assess the consistency of a 
unique identifying color associated with these substances as pure samples and 
when cut with adulterants. The inclusion of these questions would only 
increase the viability for these colorimetric reagents as a technique for 
screening of these 2-aminoindane analogues. Incorporating the final question is 
one of great importance as  the Scientific Working Group for the Analysis of 
Seized Drug’s (SWGDRUG) most recent recommendations state that in order to 
confirm the identity of a compound, the process undertaken must be based on 
the usage of validated analytical techniques, such as the analytical techniques 
listed in Table 2. 
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Table 2. SWGDRUG categories of analytical techniques  
Category A Category B Category C 
Infrared Spectroscopy Capillary Electrophoresis  Color Tests 
Mass Spectrometry Gas Chromatography Fluorescence  
Spectroscopy 
 
Nuclear Magnetic 
Resonance 
Spectroscopy 
 
Ion Mobility Spectrometry  Immunoassay  
Raman Spectroscopy Liquid Chromatography Melting Point 
X-ray Diffractometry Microcrystalline Test Ultraviolet 
Spectroscopy 
 
 Pharmaceutical Identifiers  
 Thin Layer 
Chromatography 
 
 
 
SWGDRUG stipulates that when a validated technique is incorporated 
into an analytical scheme, at least one other technique from either of the 
categories must be used (54). The highlighted portions in table 2 refer to the 
validated analytical techniques used within this study.  
 
3. Materials and Methods 
 
3.1 Materials  
 
The NARK® II reagent kits were obtained from Sirchie© Group, Evident©. 
The NARK® II progressive system for drug identification included: Marquis 
Reagent (NARK® 2001), Nitric Acid Reagent (NARK® 2002), Modified Scott 
Reagent (NARK® 2007), Mecke’s Modified Reagent (NARK® 20011), Talwin 
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(Pentazocine) Reagent (NARK® 20012), Methamphetamine, MDMA (NARK® 
20015), Mandelin Reagent (NARK® 20022), MDPV “Bath Salts” Reagent (NARK® 
20024) and Mephedrone “Bath Salts” Reagent (NARK® 20025) in boxes of 10. 
The acid neutralizer was also purchased (NARK® 2006) in a 2-ounce bottle.  
The chemicals and solvents used in this study for the In-House reagents 
were manufactured by Fisher Scientific© and included methanol (99.9% purity), 
37% formaldehyde (formaldehyde: water, v/v), concentrated sulfuric acid, 
selenious acid, sodium molybdate, and cobalt (II) thiocyanate. Certified 
reference materials (CRM) of the hydrochloride salts of 5-IAI and MDAI were 
manufactured by Cayman Chemicals©. The certified reference materials of the 
hydrochloride salts of 1-AI and 2-AI were manufactured by Pflatz & Bauer© and 
Alfa Aesar©, respectively. The adulterants that were used in this study were 
acquired from a number of manufactures. Meta-Chlorophenylpiperazine HCl 
(m-CPP), metoclopramide HCl, niacinamide, nicotinamide and ammonium 
metavanadate were manufactured by Fisher Scientific©. Levamisole HCL, 
lidocaine and procaine were manufactured by MP Biochemicals©. Benzocaine 
was manufactured by Chem-Service©. Acetaminophen was manufactured by 
Cerilliant©. Caffeine was manufactured by Sigma-Aldrich©. Dextromethorphan 
was obtained from Boston University Biomedical Forensic Science Laboratory 
as part of an extraction of over-the-counter cough medicine.  Other materials 
included disposable transfer pipettes, 2.0 ml Eppendorf© tubes, 3x4 porcelain 
spot plates, spatula, metric pipettes, GC vials, GC vial inserts, tweezers, 
Kimwipes©, black screw top vials, hot plate, stir bar, 100ml screw top beakers, 
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10ml screw top vials, Olympus© SP 500UZ digital camera, vortex mixer, 
volumetric flasks, glass dropper, and an analytical balance. 
 
3.2 Preparation of In-House Color Test Reagents 
In-House color reagent formulations are summarized in Table 3.  Color 
reagent formulations were supplied by the National Institute of Justice (NIJ) 
standards, NIJ Standard-0604.01 titled, “Color Tests Reagents/Kits for 
Preliminary Identification of Drugs of Abuse” (55).This manual specifies the 
procedures  and performance criteria for the use and validation of colorimetric 
testing reagents and equipment used in forensic color tests. Color reagent tests 
were prepared in the manner described in NIJ-STD-0604.01. The color reagents 
were stored in 100ml screw top beakers and stored at room temperature for the 
duration of the experimentation (~6months).   
 
 
Table 3. In-House color test reagent formulations 
 
Color test Reagent Formulation 
Marquis Reagent 5ml of 40% Formaldehyde(Formaldehyde:water,v/v) 
in concentrated sulfuric acid 
 
Cobalt 
Thiocyanate 
2.0% w/v cobalt (II) thiocyanate in distilled water 
Froehde’s 
Reagent 
0.05% w/v sodium molybdate in hot concentrated 
sulfuric acid 
 
Mecke Reagent 1% w/v selenious acid in concentrated sulfuric acid 
 
Mandelin’s 
Reagent 
1% w/v ammonium metavanadate in concentrated 
sulfuric acid 
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3.3 Sample Preparations of Certified Reference Materials 
Sample preparation of the aminoindane and adulterant certified 
reference materials (CRMs) varied based on how they were manufactured and 
packaged. 5-IAI and MDAI were received as 5mg and 1mg powders, respectively. 
1mg/ml solutions were created for each of the aminoindane and adulterant 
CRMs. 1mg/ml solutions were created by either serial dilutions, weighing out 
the appropriate quantity or direct dilution of the CRM with the appropriate 
solvent (MeOH) in a pre-labeled screw top vial. The screw top vials containing 
the aminoindane or adulterant working standards were stored in a refrigerator 
at ~4⁰C for the duration of experimentation (~6 months). 5-IAI and MDAI 
experiments were carried out at room temperature and all color tests were 
conducted in clean white porcelain spot trays.  
 
3.4 Evaluation of NARK® II Reagent Kits and In-House Colorimetric 
Reagents 
Initial observations of the NARK® II reagent kit protocols noted that 
various test pouches may contain one or more colored reagents. It was 
necessary to evaluate each test in the absence of analytes to determine what, if 
any, color development occurred. This is an imperative aspect of evaluation of 
the NARK® II Reagents kits, as the testing protocols indicated the reagents alone 
could create a color change (56). Testing of the reagent kits were conducted by 
using one pouch from each test kit and were performed in accordance with the 
directions for the individual test in the absence of any analytes. When a test 
35 
 
contained one or more colored reagents, only changes in color were noted. 
Testing of the In-House colorimetric tests was conducted in the same manner, 
noting any change of color.  
Some of the kits used in this project screen for the drugs of abuse that 
contained an amine groups within their structures, i.e. amphetamine, 
methamphetamine, MDA, or MDMA. Many of these kits contain well-known 
reagents that are commonly used on a variety of sample sets encountered in 
fieldwork, i.e. capsules, tablets, powders, plant materials or liquid samples. 
These tests can be performed either in the individual reagent kit package or in a 
spot plate by using a few milligrams of the powder, capsule, tablets or plant 
material in combination with the colorimetric reagent(s). In the case that a 
liquid sample is encountered, a few drops of the unknown solution can be used 
in combination with the colorimetric reagent(s) to observe a color development, 
if any. NARK® II kits are designed to be sensitive to very small quantities of the 
analyte of interest, described as a few grains of analyte from the NARK® II 
testing protocol (57). It was decided that the initial evaluations of the NARK® II 
kits and color reagent formulations would be conducted in a similar manner, 
when determining the color development for a particular combination of reagent 
and analyte of interest(s). A 25µl aliquot of the prepared 1mg/ml standard was 
pipetted into a clean porcelain well plate. The solution was allowed to evaporate 
to dryness under room temperature as recommended by the NIJ Standard 
0604.01. Each analyte of interest was tested with all of the kits and In-House 
color reagent formulations and the color development, if any, was recorded (see 
results and discussion). 
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3.5 Procedures for Color Spot Test Examinations 
3.5.1 Quantitative Study  
The objective of this study was to determine which colorimetric reagents 
elicit a color change for 5-IAI and MDAI as well as determine the lowest quantity 
of target analyte needed to visualize color development. The methods used in 
this study were adapted from the NIJ Standard 0604.01 (55). Only the NARK® II 
kits and In-House color reagents that generated a color development with the 
analytes of interests were tested further. According to NIJ standards, it 
recommends that when determining the LOD, a 1µg/µl solution of the target 
analyte should be prepared in the solvent of choice and tested with the 
appropriate reagent (55). If warranted, the amount used can be decreased or 
increased based on the sensitivity of the reagents being tested. The quantities 
used in this study were measured out by aliquoting different volumes of the 
1mg/ml aminoindane working standard into the well. For the working drug 
standards, the organic solvent was allowed to evaporate to dryness before the 
color spot test was performed as recommended by the NIJ standard 0604.01. 
NARK® II reagent kits are packaged in glass ampoules for single test field 
purposes. The reagent tubes were broken into 2.0ml Eppendorf© tubes. 
Disposable pasteur pipettes were used to transfer 2-3 drops of reagent 
solution(s). The reagent solution(s) were applied to wells containing the 
evaporated drug standard and a blank well. If a NARK® II reagent test contained 
more than one reagent ampoule then the NARK® II protocols would be 
37 
 
referenced to determine the appropriate sequence to use the reagents. The tray 
was slightly agitated and any color change that was observed immediately was 
recorded. It was determined that 25µg was a sufficient quantity of target analyte 
to elicit a color change. This was the initial starting amount of target analyte 
used to determine whether a color change would occur for any of the 
colorimetric reagents used. Depending on whether a color change was observed 
at that mass of target analyte, the quantity of target analyte was either 
increased or decreased in order to determine the LOD. The procedure was 
conducted until the lowest quantity of target analyte was detected for any of the 
colorimetric reagents used. The remainder of the three quantities that were 
used in this study was a multiple of the lowest quantity determined. This was 
done so that high and low ranges of target analyte were analyzed. The time it 
took for any color change to occur was noted as well. It is important to note the 
following factors when observing the generated color: the basic color 
development, any color change (e.g. orange to brown), or the lack of color 
development. 
The color reactions were described with appropriate descriptive words 
and documented by taking pictures. The results of all the tests were recorded 
photographically after the addition of the final color reagent as directed by 
NARK® II user instructions. All spot test wells were photographed at 30 
seconds.  
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3.5.2 Specificity Study  
For reagents used in this thesis, a final color was determined, if any, via 
the concentration study. The reagents that developed a color change indicating 
the presence of aminoindane CRMs were used for the specificity tests.  A 
solution containing an aminoindane working standard and one of five selected 
adulterants in a 1:1 ratio (v/v) was created and thoroughly mixed using a vortex 
mixer. In was determined in the previous section that 25µg of unadulterated 
target analyte was a sufficient quantity to visualize a color development for the 
colorimetric reagents that had a reaction. The results of this quantity of target 
analyte were used for comparison purposes to the mixtures created in this 
study. To compensate for half the concentration of target analyte that was made 
because of the mixture, twice the volume used in the concentration study was 
used (50µl) in this study. This was done so that an equivalent mass of 
aminoindane CRM was used for the accurate color comparisons to the control 
samples in the concentration study. For the contrived mixture solutions, the 
organic solvent was allowed to evaporate to dryness before the color spot test 
was performed.  
 
3.6 Development of GC-MS Analytical Parameters  
 The Biomedical Forensic Science Laboratory has a standard GC-MS 
analytical method that is designed for the analysis of basic drug compounds. 
Preliminary tests were performed to assess the applicability of this method to 
identify the analytes of interest used in this study. 50µg/ml solutions of 1-
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aminoindane (1-AI), 2-AI, 5-IAI and MDAI were created in methanol and 
analyzed using the basic drug method. 1-AI and 2-AI are structural isomers of 
each other and are homologs of MDAI and 5-IAI. These compounds were added 
to the GC-MS studies to determine whether these compounds would be suitable 
as internal standards. The resulting chromatography of the selected 
aminoindane compounds showed complete baseline resolution with sharp and 
distinct peak shapes, but it was observed that 1-AI and 2-AI could not be 
resolved by this method, as these compounds are structural isomers.  
 This method proved to be successful in detecting the individual 
aminoindane compounds. The preliminary chromatographic data revealed that 
5-IAI had the greatest affinity to the stationary phase and eluted off the column 
last at approximately 6.20 minutes. The total run time for the basic drug 
method is 12.50 min. The difference between the time of the last eluting 
compound and the end of the method is 6.40 minutes. For the purpose of 
developing an accurate and rapid method for the analysis of the analytes of 
interest in a contrived mixture, a few alterations were made to the GC-MS 
parameters.  It was identified that the target analyte 5-IAI and the adulterant 
acetaminophen had co-eluting peaks between the 6.00-6.30 min periods of the 
analysis. It is speculated that these particular compounds have similar 
affinities for the stationary phase, which results in co-elution when interpreting 
the total ion chromatogram (TIC) of this sample. This elution problem was noted 
and the reasons for co-elution were assessed later. The temperature program 
was modified to ensure better peak resolution between the 13 components in 
the mixture. GC separations in a GC-MS system are achieved with the use of a 
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temperature program. A temperature program can be advantageous to the 
analysis of a complex mixture such a parameter can result in improved 
component separation, peak resolution and a reduction in the overall time of 
analysis compared to an isothermal temperature program (58). The splitless 
injection mode is a useful technique for the analysis of trace compounds. This 
technique can be used in method development for the quantitative analysis of 
these compounds. Since high concentrations of analyte were used in this study, 
the injection volume was set at 1µl to avoid overloading the column. Scan and 
selected ion monitoring (SIM) modes were used in this method. It can prove 
beneficial to collect data in both scan and SIM modes during data acquisition. 
Scan mode was used to acquire unambiguous confirmation of the analytes of 
interest within the mixture as well as gain information on the qualifier ions that 
would be used in the SIM mode. By tuning the mass analyzer to detect selected 
ions of a specific m/z ratio, SIM mode increases the mass spectrometers’ 
sensitivity more so than the scan mode parameter. SIM mode allows for more 
time spent measuring ion currents of interest rather than over a broader 
measurement of ions as in the scan mode (59). In comparison to the TIC, in 
which peaks are plotted for all ions within a given mass range, SIM mode allows 
for selected ions to be plotted for the generation of a chromatogram, which is 
ideal for targeted-compound analysis. SIM mode was applied to generate a 
chromatogram of selected ions and establish a baseline for the quantification of 
lower concentrations of targeted compounds in a complex mixture. The final 
GC-MS analytical method, referred to as AIN.M, can be seen in Table 4. 
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Table 4. Optimized parameters of AIN.M GC-MS analytical method 
Parameter AIN.M 
Total run time 10 min 
Temperature Program 90°C for 1 min, then 36°C/min for 6 min, 5°C/min for 
30 sec, 36°C/min to 300°C, hold for 3 min 
Injection volume 1µl 
Inlet Mode Splitless 
Inlet Temperature 250°C 
Pressure 4.5099 psi 
Average Velocity 28.931cm/sec 
Solvent Delay 2:30 min  
MS Mode Scan and SIM 
Low Mass 50.00 atomic mass unit(amu) 
High Mass 550.00 amu 
SIM ions 133.10 m/z, 177.10 m/z, 259.00 m/z 
 
GC-MS analysis of the 2-aminoindane analogues and selected 
adulterants was performed using an Agilent Technologies 7890A GC System 
and a 5975C Inert XL EI/CI MSD (Agilent Technologies, Santa Clara, CA). 
Samples were injected into the GC using a HP 7683B Series Injector. 
Separation was achieved with an Agilent Technologies 19091S-433 (5% phenyl)-
methylpolysiloxane GC capillary column (30m x 0.25µm x 0.25mm) (Agilent 
Technologies, Santa Clara, CA.) with helium as the carrier gas at a constant 
flow rate of 1.0ml/min. “MSD ChemStation G1701EA E.02.00.493” software 
was utilized to aid in data interpretation. 
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3.6.1 Preliminary Analysis of 5-IAI and MDAI 
 
Calibration standards were created using CRMs at 1mg/ml and further 
diluted in methanol to create the following calibration curve standards: 
150µg/ml, 100µg/ml, 75µg/ml, 50µg/ml, 25µg/ml, 10µg/ml, and 1µg/ml of 1-
AI, 2-AI, 5-IAI and MDAI. Calibration standards (adulterant study): 2.5mg of 
each component (benzocaine, lidocaine, caffeine, m-CPP, levamisole, 
dextromethorphan, procaine, are metoclopramide) were weighed out accurately 
into a 20ml screw top vial and diluted with 12.5ml of methanol to give a 
solution containing each component at 200µg/ml. This solution was further 
diluted with methanol to give calibration standards ranging from 100µg/ml to 
1µg/ml. Acetaminophen was obtained as a 1mg/ml standard and was further 
diluted with methanol and mixed with the previously made adulterant 
solutions. The linearity studies were conducted in triplicate. The lowest 
calibrator used is this study is significantly higher than that of the calibrators 
that would be typically used in forensic laboratories. The purpose of this study 
was to establish a reference point for quantitative analysis, which can be 
improved upon by using either an internal standard or SIM mode to develop a 
quantification method for the determination of the LOD/ limit of quantification 
(LOQ) on this instrument.  
  
43 
 
4. Results and Discussion 
4.1 Evaluation of NARK® II kits and In-House Colorimetric Reagents 
 Whether an ‘unknown’ substance is encountered in the field or in a 
laboratory setting, presumptive tests can provide valuable information in the 
earliest stages of analysis. Narcotics identification systems such as the NARK® 
II’s progressive system for drug identification are designed to function as a 
portable narcotics test to aid law enforcement whenever the need for its 
capability might arise (57). In spite of the shortcomings of color tests, such as 
false positives and negatives, unexpected colors and subjectivity of inherent 
color interpretation, they are still useful in answering preliminary questions 
quickly in fieldwork (48). To minimize the occurrences of false positives and 
false negatives, the general NARK® II protocol suggests that the use of these kits 
be conducted in an orderly, stepwise fashion and to refer to the NARK® II 
Colorimetric Chart to assist in employing the next step option to confirm the 
presence of a specific targeted drug (56). 
 The methodology behind the colorimetric tests that were selected for this 
study was based on some of the structural similarities (i.e. aromatic ring, amine 
functionality or methylenedioxy moiety) that MDMA shares with 5-IAI and 
MDAI. Reactions with colorimetric reagents and ATSs are well documented in 
literature. This provided insight as to what NARK® II reagent kits and In-House 
color reagent preparations would have the potential to elicit a color response. In 
contrast, the structural difference between 5-IAI and MDAI as seen in Figure 6, 
could very well elicit a different color response or no color change at all.  
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Figure 4. Highlight of the structural differences between MDAI and 5-IAI 
 
The base structures of both 5-IAI and MDAI are the same. Both of the 
compounds are polycyclic aromatic compounds, sharing a 2, 3-dihydro-1H-
indene backbone structure. An amine functional group is attached at the 
carbon-2 position of the indene structure. The difference between these two 
compounds is that MDAI has a methylenedioxy bridge attached to the carbon-5 
and carbon-6 position of the aromatic ring whereas 5-IAI incorporates iodine at 
the carbon-5 position. In addition, a major consideration is that MDMA has a 
secondary amine moiety while both 5-IAI and MDAI incorporate a primary 
amine moiety. 
A consideration for the range in color development is whether the reagent 
mixture is an oxidizing agent. Selenious acid, a component for the Mecke 
Reagent, is a powerful oxidizing agent that forms various color complexes with 
compounds that are susceptible to oxidation (60). Sulfuric acid is a commonly 
used component in colorimetric reagents due to its nature of inducing a 
number of reactions such as esterification, oxidation, dehydration, and 
hydrolysis (49). In order to reach the ultimate goal of producing a spot test for 
5-IAI and MDAI, it is essential to look at all of the tests that react with the 
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analytes of interest, not just those reagents that follow the step-wise 
progression suggested by the NARK®II Colorimetric Chart.  
The first experiment that was performed was to evaluate NARK® II and 
In-House color reagents in the absence of any analyte to determine if there was 
any unexpected color development. Testing of the reagent kits was conducted 
by using one pouch from each test kit box and was performed in accordance 
with the directions for the individual test in the absence of any analytes. When 
a test contained one or more colored reagents, only changes in color were noted. 
The testing of the In-House colorimetric tests was conducted in a similar 
manner. Transfer pipettes were used to add color reagent solutions to clean 
porcelain spot plates, only changes in color were noted. It was determined that 
in the in absence of any analyte, both reagent systems did not cause an 
unexpected reaction. Cross reactivity amongst the reagents during the 
identification of potential drugs of abuse could be troublesome, due to the 
subjectivity of color interpretation. If any reagent test kit were to prematurely 
react and result in a color change prior to the analyte of interest being 
assessed, it could potentially lead to the misinterpretation of results. This step 
was imperative before proceeding on with the next portion of the study. 
The next set of experiments conducted was performed with 5-IAI and 
MDAI standards. All colorimetric reagent tests employed in the first evaluation 
step were tested in the presence of analyte to assess whether or not a color 
change would be observed. Marquis, MDPV, Mecke and Talwin reagents were 
the only tests to produce a color change for 5-IAI. All of the NARK® II reagents 
used in this study reacted with the MDAI standards. Table 4 shows the 
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preparations of the 5-IAI and MDAI standards, in which a produced color 
change was witnessed with the various NARK® II reagent kits. It should be 
noted that each test was conducted independently and in no particular order. 
The common reagent tests that were shown to produce a color change for both 
aminoindane standards are highlighted in Table 5.  
 
Table 5. NARK® II reagent evaluations for the aminoindane analogues 
 Mandelin Marquis MDPV Mecke Nitric Talwin 
5-IAI NR Br Br Y/G NR Y 
MDAI G/Br Y/Br G/Y Y/Br Y Ol ->Y/G 
 
Key: NR = no reaction; Br= brown; G=green; Ol=olive drab; Y= yellow 
Shaded area- common reagents tests that reacted with 5-IAI and MDAI 
 
In-House colorimetric tests produced color changes for the 5-IAI and 
MDAI standards as well. Interestingly, the 5-IAI standards had only one reagent 
that reacted with it, the Marquis reagent preparation. A preparation of Mecke 
reagent consisting of selenious and sulfuric acid was created, a test that was 
used the NARK® II and In-House reagent systems. Unfortunately, this 
preparation did not produce a color change like its NARK® II reagent 
complement. This could be a product of different formulations used to create 
the reagent. MDAI standards, in a similar pattern with the NARK® II reagents 
were able to elicit changes for all of the reagents used. Table 6 shows the 
results of the reaction between the target analytes and the In-House reagents. 
The reagents that reacted positively for both standards are highlighted in Table 
6. 
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Key: NR = no reaction; Br= brown; G=green; Ol=olive drab; Y=yellow  
Shaded area- common reagents tests that reacted with 5-IAI and MDAI 
 
 
The Marquis test is the most versatile and is generally the first color test 
used in the analysis of an unknown compound suspected of being an illegal 
substance.  The Marquis test is typically used to indicate the possible presence 
of amphetamine, methamphetamine or MDMA by reacting with them to form a 
distinctive orange/red/brown, orange, or a dark purple/black color, 
respectively (45, 61). In the presence of the Marquis reagent, 5-IAI developed an 
immediate brown color. In the case of MDAI, a rapid yellow/brown color 
formation was observed. The color development observed would indicate the 
presence of an ATS. Although the chemistry involved with this reagent is 
considered complex and is not completely understood. Based on the previous 
colorimetric test research conducted by Suzanne Bell, ATS compounds in the 
presence of Marquis reagent, which contains formaldehyde, are known to 
produce a color change as a result of a dimer type product formation of the 
original structure (45). Figures 5 and 6 depict the speculated reaction 
mechanism of both MDAI and 5-IAI with the Marquis reagent. In the process of 
achieving a color development, formaldehyde is added to an aromatic ring with 
a primary amine moiety. The intermediate formed from this reaction is an 
alcohol. This intermediate is used later on in the reaction mechanism to form 
Table 6. In-House color reagent evaluations for the 
aminoindane analogues  
Compound Froehde Mandelin Marquis Mecke 
5-IAI NR NR Br NR 
MDAI G/Y 
 
G Y/Br Ol->Y/G 
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the color producing dimer product. Through the loss of a water molecule, a 
nucleophile is created in the form of a carbocation. This carbocation is can be 
subjected to nucleophilic substitution by the alcohol intermediate that was 
created earlier in the reaction mechanism. The dimer formed at the completion 
of this reaction is responsible for the color development.  
 
 
Figure 5. Speculated reaction mechanism of MDAI with Marquis reagent 
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Figure 6. Speculated reaction mechanism of 5-IAI with Marquis reagent 
 
When analyzing these illicit substances with the Marquis reagent, one of the 
possible reactions that would prompt further testing is the brown and 
yellow/brown color development, indicating an ATS. The colors produced by 5-
IAI and MDAI are distinctive, but to further differentiate these compounds, 
additional color tests are required.  
 
 
 
 
50 
 
4.2 Quantitative Study  
4.2.1 Analysis of 5-IAI using NARK ® II and In-House Reagent Systems  
This experimental study was designed to assess what colorimetric 
reagents would elicit a color development for 5-IAI. This experimental study also 
assessed the consistency of the color intermediates observed from the initial 
evaluations of the NARK® II individual kits and In-House color reagents at 
various measured quantities of pure 5-IAI and MDAI standards.  
 
 
Figure 7. Quantitative study of 5-IAI using NARK® II reagents, Note: All of the tests not 
shown yielded no reaction or images were difficult to capture 
 
5-IAI standards produced comparable results to the initial observations for 
NARK® II test kits from the evaluation stage, yielding a positive result for all 
four quantities when tested with Marquis, MDPV and Talwin reagents (62.5µg, 
50µg, 25µg, and 12.5µg) (Figure 7). Because the lowest measured quantity that 
was detectable by Marquis, MDPV, and Talwin reagents was 12.5µg, the LOD 
for these particular tests under these conditions was considered to be 12.5µg. 
Positive results were also observed for 5-IAI with the NARK® II Mecke reagent 
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(not represented in figure). Mecke and Talwin reactions are not represented in 
Figure 7. There was a rapid color development indicating the presence of 5-IAI 
for these tests and then dissipated quickly. This made capturing of the 
resultant color very difficult. However, only three out of the four measured 
quantities yielded a color development (62.5µg, 50µg, and 25µg) for the NARK® 
II Mecke reagent test. The LOD for the Mecke reagent was considered to be 
25µg. At the lowest measured quantity of 5-IAI, the color development 
proceeded slowly, relative to the higher measured quantities. This was the case 
for the Marquis and MDPV test kits. Talwin and Mecke reagents reacted with 
the 5-IAI standards nearly at the same rate. The discrepancy in the rate of color 
development is a function of the reagent solution used in the colorimetric 
reagent. If colorimetric reagent consisted of a strong oxidizing reagent then the 
strong oxidizer would be able to influence the reaction rate. When the highest 
mass was added to the well, the color development was nearly instantaneous 
and was the most vibrant color observed. The results for the In-House color 
reagents were also comparable to the initial evaluation stages and the results 
can be seen in Figure 8. 
 
 
Figure 8. Quantitative study of 5-IAI using In-House reagents 
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Interestingly, there were some similarities and differences between the Marquis 
NARK® II test kit and the In-House reagent complement. The similarities and 
differences between these particular tests dealt with the LOD and intensity of 
color development. In an examination of the In-House Marquis reagent, positive 
results were observed for all quantities of 5-IAI standards (Figure 8). Thus, 
under these conditions the LOD for this particular reagent was determined to 
be 12.5µg, which is similar to the LOD for the NARK® II Marquis reagent. A large 
discrepancy was noted between the color intensities for both reagents 
throughout the range of 5-IAI measured quantities, while it remains true that 
the most vibrant color was observed at the highest measured quantities of 
analyte added as shown in Figure 9. 
 
Figure 9. Comparison of 5-IAI quantities for Nark® II and In-House Marquis reagent 
 
The overall color intensity for the In-House Marquis reagent positive reactions 
rapidly diminished from a vibrant and clearly visible brown to a very faint 
brown at the LOD. The intensity change for the In-House Marquis reagent was 
first observed at the two highest measured quantities of 5-IAI standards 
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(62.5µg-50µg). The drop in intensity could be attributed to the fact that the In-
House formulation was not sensitive enough for this particular analyte of 
interest. The colorimetric reagents formulation is a possible factor in color 
intensity. The ratios used in the colorimetric reagent formulations would have 
some impact on the color intensity. While the general NIJ standard 
recommended reagent tests have been validated for particular compounds, it 
was interpreted that similar NARK ® II tests have been modified to elicit optimal 
color development. 
Aside from any reagent formulation considerations, based on the data gathered 
for the NARK® II and In-House Marquis reagent tests, it was determined that 
the intensity of color development and time of developed color were dependent 
on the mass of 5-IAI in the well. The higher masses developed the most intense 
color in the shortest period. While, the lowest masses tested had the weakest 
color intensity and took the longest time to develop the desired color.  
 
4.2.2 Analysis of MDAI using NARK ® II and In-House Reagent Systems  
 
Figure 10 shows the results of the quantity study of MDAI using NARK® 
II reagents. MDAI standards produced comparable results to that of the initial 
NARK® II kit evaluation stages, yielding a positive result for all selected 
measured quantities when tested with Mandelin, Marquis, MDPV, Mecke, Nitric 
and Talwin reagents (25µg, 10µg, 5µg, 1µg) (Figure 10). Because the lowest 
measured quantity that was detectable by the six NARK® II reagents was at 1µg, 
the LOD for these particular tests under these conditions were considered to be 
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1µg. Some of the general trends that were identified with the analyses of the 5-
IAI quantity study held true for the MDAI quantity study as well. 
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There was minimal color disparity through the ranges of quantities, 
which indicates that the color generated for any of these particular tests 
indicate the presence of MDAI consistently. The one case in which color 
perception varied the greatest occurred when the MDAI standards were tested 
with the Marquis Reagent. When the highest measured quantity was added, the 
color development was nearly instantaneous and was a medium 
yellow/brownish color. In contrast, the remainder of the MDAI quantities used 
for this specific reagent generated a bright yellow color. The appearance of the 
brownish coloration observed only at the 25µg quantity of MDAI is considered a 
complementary color development of the Marquis reagent. The yellowish 
coloration observed at the lower masses of MDAI was more evident than the 
complementary color development. The lower measured quantities were 
consistent in the “secondary” color development. The persistence of the 
yellowish coloration is the result of the main reaction between formaldehyde 
with the aromatic ring of MDAI, as part of the speculated reaction mechanism 
with Marquis reagent.  
The time that it took for the majority of these tests to show color 
development was very quick. It was expected that at the higher quantities of the 
MDAI standards, the time it would take for the color development would 
decrease. This trend was expected to be inversely proportional as the quantity 
of analyte decreased. The only occurrence in which the trend held true was for 
the NARK® II Mandelin reagent tests. The lowest quantity in this series took 
nearly 15 seconds to develop before it was determined to be a positive result. 
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The other NARK® II reagents employed in this study developed their respective 
color at the lowest quantity within a matter of a few of seconds. The average 
time it took all six NARK® II reagents to react with 1µg of MDAI was 3.33 
seconds. The combination of the LOD, reaction speed, and vivid colors seen in 
these tests that were performed are excellent examples of the desired 
development, as it would be less likely to be mistaken for the reaction that is 
expected with the usual analyte of interest.  
The last installment of this experimental section is the examination of 
MDAI quantity in the presence In-House colorimetric reagents. Figure 11 will be 
referenced when discussing these results.  
 
Figure 11. Quantitative study of MDAI using In-House reagents 
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All of the In-House colorimetric reagents that were used in the analyses of the 
four MDAI quantities developed the desired colors that were observed in the 
evaluation stage. The LOD for all reagents used in this part of the study was 
determined to be 1µg, similar to that of the NARK® II test kits. Each of the In-
House reagent tests used in this experiment generated a color that was close in 
proximity to the color development of the highest masses used. The general 
trends observed in this part of the study were similar to the NARK® II reagent 
systems. These results indicate that both NARK® II reagents and In-House 
preparations are very sensitive and are able to detect minute amounts of 
unadulterated analytes of interests. The results also indicated that the intensity 
of the desired color is dependent on the mass of the targeted analyte in the well. 
The higher quantities developed the most intense color, while the lowest 
quantities tested had the weakest color intensity. 
Further evaluation of these tests revealed inconsistencies in color and 
intensity when compared directly next to each other. Figure 12 shows color and 
intensity disparities for the following NARK® II and in-House color reagents 
using a 25µg standard of MDAI with Mandelin and Mecke reagents. 
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Figure 12. Color and intensity comparison between two NARK® II and In-House 
reagents, Mandelin reagent (A-B) and Mecke reagent(C-D) using 25µg.  
 
In the assessment of both versions of the Mandelin reagents (Figure 12, A and 
B), it is easily discernible that there is a large color and intensity disparity 
between the results of both of these tests. The NARK® II (A) preparation, 
perceived to be a medium brown/green, is a deeper and more apparent color 
than that of its In-House (B) complement, which was perceived to be a brown 
color. In the comparison of the Mecke reagent preparations, the colors that 
developed were very vibrant and intense at the 25µg level. The area of interest 
lies in the color difference that is observed in images C (NARK® II) and D (In-
House). The color that developed when MDAI reacted with the NARK® II Mecke 
reagent was reported as a medium yellow/brown. This was noticeably different 
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from its In-House equivalent, which was more of a fluorescent yellow/green 
color.  
 Although the color and intensity differed between the NARK® II and In-
House Mandelin and Marquis reagent preparations, they were still accepted as 
positive results for the presence of MDAI. The difference in color appearance 
and intensity can be a direct result of the reagent formulation. The In-House 
reagent formulations were taken from the NIJ Standard (55) on identification of 
drugs of abuse using color test reagents. The formulas that were described in 
this report are just one of a number of adaptations used to create a particular 
color test. The variations in the reagent formulation could be the cause for the 
differences in color and intensity observed in this study. In the final comparison 
between NARK® II and In-House reagent preparations, Marquis reagent 
displayed some inconsistencies with color across the various MDAI quantities 
used. This can be seen in Figure 13. 
 
Figure 13. Comparison of MDAI quantities for NARK® II and In-House Marquis reagent  
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The color developed for both of these reagents were consistent at the MDAI 25µg 
quantity (Figure 13, 25µg column), developing a medium yellow/brown color. As 
mentioned in earlier discussions, the MDAI 10µg quantity was where a large 
difference in color was noted (Figure 13, 10µg column, row NARK® II). The 
Marquis reagent for the NARK® II system displayed a consistent bright yellow 
through the lower quantities with no indication of a brown color (Figure 13, 
25µg -1µg column, row NARK® II). When compared to the In-House complement, 
the color displayed when 25µg of MDAI reacted was a similar medium 
yellow/brown color. The remaining quantities were more consistent with the 
color that was first seen at the 25µg level for the In-House Marquis reagent. The 
developed color ranged from a medium-light yellow/brown to light-faint 
yellow/brown (Figure 13, 25µg -1µg column, row In-House).  
The consistency of the brown complementary color development with the In-
House reagent tests indicate that its appearance is in part due to the dimer 
product formed at the completion of the Marquis reagent reaction. The reagent 
formulation differences between NARK® II and In-House reagent plays a role in 
the appearance of the brown complementary color. Although, the brown 
coloration is not apparent in the NARK® II Marquis reagent at the lower masses 
of MDAI, its presence in higher masses is still an indication of the MDAI 
compound. Further research conducted with various reagent formulations 
would uncover the persistence of any complementary colors observed with 
colorimetric tests. These reagents can easily be incorporated into a testing 
sequence similar to that of the NARK® II Colorimetric Chart for the preliminary 
identification of MDAI. After testing reagents with MDAI, a partial flow chart 
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was created as a stepwise method to detect this compound in the case that law 
enforcement officers encounter this compound in the course of fieldwork (Figure 
14). The progression is listed as follows: Marquis, yellow/brown; nitric, yellow; 
Mecke, yellow/light brown; Talwin, Olive /fluorescent yellow-green; Mandelin, 
green/brown; and MDPV, green/yellow. 
 
Figure 14. Partial flow chart for color development and presumptive identification of 
MDAI using NARK® II reagent test kits 
 
4.3 Specificity Study  
4.3.1 Evaluation of Adulterants and Color Reagent Systems 
The goal of this line of testing is to address the consistency of the 
developed colors of 5-IAI and MDAI in the presence of adulterants. Due to 
current trends, illicit drugs are generally mixed with various adulterants. Only 
adulterants that would closely represent “street quality” samples were used in 
Marquis 
Mandelin 
Mecke Nitric 
MDPV 
Talwin 
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this section of the study. Research was then redirected to the commonly used 
adulterants in the manufacturing of ecstasy (MDMA) tablets/powders. This was 
a logical approach given that MDMA is the closest ATS that has similar 
biological effects to 5-IAI and MDAI. The following adulterants were acquired 
based on published articles highlighting common adulterants used in MDMA 
manufacturing: lidocaine, benzocaine, caffeine, meta-chlorophenylpiperazine m-
CPP, niacinamide, nicotinamide, and procaine (40, 41, 62). Once suitable 
adulterants were gathered 1:1(v/v) ratio of the analyte of interest to adulterant 
were created from 1mg/ml standards. This study provided insight on whether 
the adulterants used in the mixture inhibit the formation of the target analyte’s 
color-developing molecule. Reagents used in the colorimetric reagent tests are 
known to induce a multitude of reactions. When using the Marquis reagent, the 
presence of an adulterant in a mixture, with either 5-IAI or MDAI, may form a 
nucleophile that could elicit a color response. If that were the case, the color 
development of the target compound(s) could be inhibited partially or 
completely.  
Prior to assessing the consistency and any inhibitory effects of the NARK® II and 
In-House reagents in a mixture, the adulterants were tested first on their own 
with each of the reagents. This was done to establish if any of the adulterants 
would elicit a color response that may interfere with the color development for 
the analyte of interest. Tables 7 and 8 highlight the results of the NARK® II and 
In-House reagent interactions with the chosen adulterants.  
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Table 7. NARK ® II reagent evaluations for selected adulterants 
Compound Mandelin Marquis  Mecke MDPV  Nitric Talwin 
Benzocaine NR NR NR NR NR NR 
Caffeine NR NR NR NR NR NR 
Lidocaine NR NR NR NR NR NR 
m-CPP Pi NR NR NR NR NR 
Niacinamide NR NR NR NR NR NR 
Nicotinamide NR NR NR NR NR NR 
Procaine NR NR NR NR NR NR 
Key: NR = no reaction; Pi= pink  
 
Table 8. In-House color reagent evaluations for selected adulterants 
Compound Mandelin Marquis  Mecke Froehde  
Benzocaine NR NR NR NR 
Caffeine NR NR NR NR 
Lidocaine NR NR NR NR 
m-CPP Pi NR NR NR 
Niacinamide NR NR NR NR 
Nicotinamide NR NR NR NR 
Procaine NR NR NR NR 
Key: NR = no reaction; Pi= pink 
 
When 25µl of a adulterant solution was added to a porcelain plate well the only 
adulterant that reacted with consistency with both NARK® II and In-House 
reagents was m-CPP, a heterocyclic amine that has been reported to be added 
to ecstasy tablets (62). This compound developed a faint pink ring with the 
NARK® II and In-House Mandelin reagents. The resultant color was observed to 
intensify over a short period, with its most vibrant coloration occurring at ~ 
20seconds (Figure 15).  
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Figure 15. Time elapse of m-CPP reaction with NARK® II and In-House Mandelin 
Reagent using 25µg 
 
The other adulterants tested with the color kits and reagent preparations did 
not demonstrate any reactivity. 
Once the initial chosen adulterants were assessed for their cross 
reactivity, the next step was to select several of these adulterants and create 
1:1(v/v) ratio mixtures with both 5-IAI and MDAI. Five adulterants were chosen 
for the next set of experiments: caffeine, m-CPP, lidocaine, niacinamide and 
procaine. Due to the apparent color change with m-CPP and the Mandelin 
reagent, this compound was an ideal candidate to visualize any inhibitory 
effects when mixed with the 2-AI analogues. The remaining four adulterants 
were selected not based on their lack of reactivity but because they are the most 
commonly utilized adulterants in ecstasy tablet/powder manufacture. The 
selected adulterants were mixed in solution (1:1, v/v) with 5-IAI and MDAI from 
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1mg/ml standards and then subjected to both NARK® II and In-House reagents 
for analysis. 
 
4.3.2 Evaluation of 5-IAI Mixed with Selected Adulterants 
The first set of tests conducted was with 5-IAI and the five selected 
adulterants. The mixed solutions were created in an equivalent volume-to-
volume manner and testing procedures were followed as described in the 
methods section. Figure 16 depicts the results of the specificity study using 5-
IAI and selected adulterants when in the presence of the NARK® II reagents.  
 
67 
 
 
 
Figure 16. Specificity study of 5-IAI and selected adulterants using NARK® II reagents, 
Note: All tests not shown yielded no reaction or images were difficult to capture  
 
Marquis, MDPV and Talwin NARK® II kits yielded the desired color development 
that indicated the presence of 5-IAI. The Marquis reagent generated the desired 
brown color in all of the mixtures when 5-IAI was the target analyte. It appeared 
that the adulterants used did not alter the desired color development for 5-IAI 
when compared to control samples. This was also the case for the MDPV and 
Talwin kits, yielding a light brown and mild yellow coloration, respectively. The 
Mandelin reagent identified the presence of m-CPP (Figure 16, Mandelin, m-
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CPP.) but there was no indication of the presence of 5-IAI, which was expected 
because the Mandelin reagent did not initially generate a color for 5-IAI in the 
kit evaluation study. It had been previously determined that the NARK® II 
Mecke reagent test had developed a yellow/green color development for the 
presence of 5-IAI. NARK® II Mecke reagent yielded the desired color development 
indicating the presence of 5-IAI in the all of the mixtures. However, the desired 
color quickly dissipated making the capturing of the image difficult.  It was clear 
that these two compounds do not interfere with each other’s color development 
or consistency in a 1:1 ratio mixture. 
The next set of experiments evaluated the ability of the In-House color 
reagents to detect 5-IAI in a 1:1 mixture of selected adulterants. The color 
intensities of the 5-IAI mixtures were slightly more apparent in this line of 
testing in comparison to the 1:1 5-IAI mixtures used with the NARK® II 
reagents. The Marquis reagent is the only In-House reagent capable of 
presumptively identifying 5-IAI and yielded a positive brown color for all of the 
five mixtures. 
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Figure 17. Specificity study of 5-IAI and selected In-House reagents, Note: All tests not 
shown yielded no reaction or images were difficult to capture  
 
The color intensity that developed is diminished compared to the color that was 
observed in the evaluation stage. The decrease in color intensity was consistent 
throughout each of the five mixtures.  
This diminished color observed for these tests is most likely due to 
colorimetric reagent reaction to the compounds within the mixture. While all of 
the NARK® II reagents used to detect 5-IAI developed a color, it is believed that 
formation of the color-developing molecule was partially inhibited. It appears 
that the adulterant in the mixture had reacted with reagent to form a 
nucleophile. This intermediate would also react with the reagents and form a 
product that may or may not elicit a color response. This would result in 
diminished color appearance of the more favored reaction mechanism, the 5-IAI 
color formation. Without complete comprehension of reaction mechanisms for 
all of the reagents employed in the identification of 5-IAI or MDAI, it is difficult 
to say that with certainty this is the root cause of the diminished color.  
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An example where color formation was hindered is in the 5-IAI: m-CPP 
solution. The Marquis test was able to positively identify 5-IAI (brown 
coloration) without any indication of m-CPP (NARK® II, Figure 16, Marquis, m-
CPP.; In-House, Figure 17, Marquis, m-CPP.). Conversely, the Mandelin reagent 
developed a color indicating the presence of m-CPP but not for 5-IAI. The time it 
took to observe the identifying color for each of the compounds took much 
longer than the initial color development in the evaluation stages. This hinted 
that there was partial inhibition of color development. Although, it is believed 
that there is a degree of inhibition, the results showed that m-CPP has no 
visible interaction between the chemicals used in this particular test and that it 
does not completely interfere with identifying 5-IAI when using the Marquis 
reagents.  
 
4.3.3 Evaluation of MDAI Mixed with Selected Adulterants 
The color test panel was repeated with MDAI and each of the adulterants. 
All of the tests yielded the result indicative of the presumptive presence of MDAI 
(Figure 18). The overall intensity of the developed colors was slightly 
diminished. The slightly reduced color is attributed to the adulterants partially 
inhibiting the color-developing molecule for MDAI. The most consistent and the 
most vibrant of the tests conducted was the Marquis reagent. Deviations in 
color appearance were noted in two cases, the MDAI: caffeine with the MDPV 
reagent and MDAI: niacinamide with the Marquis reagent (Figure 18, Marquis, 
caffeine and niacinamide).  
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With these two particular mixtures, the desired color development was atypical 
in comparison to the color witnessed when the control MDAI was tested. There 
were several patterns observed for the In-House reagents used in this portion of 
the study (Figure 19). The In-House reagents produced a positive response that 
indicated the presence of MDAI. All four In-House reagents were determined to 
be the most consistent in developing similar color and intensity for the MDAI: 
lidocaine, MDAI: niacinamide and MDAI: procaine mixtures. The results for the 
MDAI: caffeine and MDAI: m-CPP mixtures yielded positive responses for MDAI 
but the results for these mixtures lacked in their overall color appearance and 
intensity. These are examples that suggest there is some interaction between 
the adulterant in the mixture and the reagents. This would result in partial 
inhibition of the color formation of the target analyte.   
73 
 
 
Figure 19. Specificity study of MDAI and selected adulterants using In-House reagents 
 
In the case of the MDAI: m-CPP mixture, both compounds were detected 
when a 2-3 drops of Mandelin reagent was added to the well. The manner in 
which the overall color development occurred was intriguing. As the initial 
drops of Mandelin reagent solution were added to the well containing the dried 
mixture, all indications led to a positive response for the presence of MDAI. A 
very clear, small, greenish ring in the center of the well appeared, which 
correlated to previous test results with MDAI for this particular reagent (Figure 
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20, A). The greenish color seen was short-lived and lasted for a brief period of 
time (~2 seconds). 
 
 
Figure 20. 1:1(v/v) solution of MDAI (A) and m-CPP (B) reaction with NARK® II 
Mandelin reagent using 25µg  
 
Shortly after, approximately 10 seconds into the observation of the reaction, a 
faint pinkish brown color developed around the outer rim of the Mandelin 
reagent. This faint pinkish color indicted the presence of the compound m-CPP 
(Figure 20, B.). This two-color reaction was also seen for the In-House Mandelin 
reagent. In the evaluation of this reaction, there were slight differences in the 
overall color development. After drops of the In-House Mandelin solution were 
added to the designated well for this contrived mixture, a faint greenish brown 
color developed (Figure 21, A). 
 
 
 
Figure 21. 1:1(v/v) solution of MDAI (A) and m-CPP (B) of In-House Mandelin reagent 
using 25µg 
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The faint greenish brown was reported as a positive reaction for MDAI. In 
a similar manner to the NARK® II Mandelin reagent reaction, the developed 
color for this test was short-lived, lasting approximately 3 seconds. Several 
seconds had passed (~10 seconds) before the development of a faint pinkish 
color indicating the presence of m-CPP was observed (Figure 21, B). The color 
and intensity difference between the two Mandelin reagent systems is attributed 
to differences in reagent composition and interactions of those reagents with 
the compounds within the mixture.  It is a positive sign that both NARK® II and 
In-House Mandelin reagent preparations were able to develop the two separate 
colors for the components in the mixture. While the initial color development 
representing MDAI was brief, it still proves that using either reagent system can 
be used to identify this targeted analyte of interest in the presence of an 
adulterant that yielded its own distinct color response for a particular reagent. 
 
4.4 Analysis of 2-Aminoindane Analogues by GC-MS 
Gas chromatography coupled to a mass spectrometry was used to detect 
and identify the 2-aminoindane analogues, 5-IAI, MDAI, and assess the 
potential internal standards 1-AI and 2-AI. Retention times (rt) and mass 
spectral profiles of the standards: 1-AI, 2-AI, 5-IAI and MDAI were established 
and presented in Table 9. 
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Table 9. Key ions for the compounds of interest  
Compound Retention time (rt) 
(min) 
EI+ generated ions 
(m/z) 
1-Aminoindane 4.25(t0=0) 132,116,115,117,104,133*,77 
2-Aminoindane 4.27(t1=1.005) 133*,116,91,132,116,115,118 
MDAI 5.70(t2=1.341) 160,177*,149,130,91,135,116 
5-IAI  5.99(t3=1.409) 259*,115,117,105,242,132,77 
*=Molecular ion. Ions are in order of decreasing abundance 
 
The rt values were referenced to one another with the first eluting 
compound as time at 0 (t0).  The t-values for the remainder of the eluting 
compounds were determined by tx/t0, where tx represents rt of the next eluting 
compound. The rt is presented in this manner because rt values will vary 
significantly with a changeover of instruments or by general GC-MS 
maintenance. The rt values of the later eluting compounds relates to the 
separation behavior of the compounds when based on 1-AI, which is t0. 2-AI 
being a structural isomer of 1-AI has a t-value that is close to one, indicating 
that this compound co-eluted with 1-AI.  These compounds are not significantly 
retained by the stationary phase, which accounts for the similar but distinct 
migration rates. The separation behavior of the compounds can be observed in 
Figure 22c.   
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1-AI and 2-AI were assessed as potential internal standards for 5-IAI and MDAI. 
These two compounds displayed similar behavior characteristics to the analytes 
of interest. It was determined that for any further quantification studies, 2-AI 
would be the most suitable as an internal standard. Not only does 2-AI share 
the 2, 3-dihydro-1H-indene backbone structure, 2-AI also has a similar 
fragment loss of a NH3 that has a reasonably intense ion peak. These are key 
features when using a chemically similar compound as an internal standard. 
In the mass spectra of the aminoindane compounds, the molecular ions 
are labeled with an M+ annotation (Figure 23, 24, 25). The mass spectra for the 
structural isomers 1-AI and 2-AI appeared to be similar as expected. Upon 
closer examination of the mass spectral data for 1-AI and 2-AI, there is an 
unusual abundant peak observed next to the M+ ion at m/z 132.0 for the 1-AI 
compound. This peak correlates to a loss of a hydrogen radical ([M-1] or [M-H]) 
through α-cleavage (59). The presence of a [M-1] fragment is consistent with the 
presence of nitrogen because N-H readily breaks in the “harsh” conditions of 
the MS (59, 63). The loss of the hydrogen radical in 1-AI originates from the 
carbon-1 position that is bonded to the amine moiety. The loss of [M-H] is 
stabilized by the pi electrons of the adjacent aromatic ring. The observed [M-H] 
fragment in the 2-AI mass spectrum (Figure 23 B.) is not as prominent because 
the hydrogen at the carbon-2 position is more difficult to remove under EI 
conditions. Due to the location of the amine moiety in 2-AI from the aromatic 
ring the hydrogen radical loss is not as easily stabilized as it would be in 1-AI 
(59, 64). The electron configuration of structural isomers can differ significantly, 
which could alter ionization energies and be the reason as to why there is such 
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a disparity between the [M-1] ion abundance for 1-AI and 2-AI (59, 65). In the 
1-AI mass spectral data, there is also a large disparity between [M-1] ion peak 
abundance at m/z 132.0 and the M+ ion peak abundance at m/z 133.0. Watson 
et al. stated that improved M+ ion peak data can be obtained by using low 
electron ionization energy (59). This is achieved by reducing the energy of the 
electron beam to a level that is near the ionization potential of the compound. 
Fragmentation of the M+ ion would diminish because there is less excess energy 
absorbed as opposed to using a 70 electron volts (eV) ionization potential. This 
would make the 1-AI M+ ion more stable and the most abundant peak relative to 
the ions in the spectra (59). The [M-1] ion peak will still be present using low 
electron ionization energy but only in trace amounts. With the improvement of 
the M+ ion peak by low electron ionization energy, detection limits would suffer 
because the ionization efficiency is directly proportional to the ionization energy 
(51, 59).   
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Figure 23. Mass spectrum of 1-AI (A.) and 2-AI (B.) 
 
The 5-IAI and MDAI MS data was not available in the NIST database that 
was used in this study; however, it was determined from the certified reference 
standards, (Figure 24 and 25) which showed the expected molecular ion of m/z 
259.0 and 177.0 for 5-IAI and MDAI, respectively. 
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Figure 24.Mass spectrum of 5-IAI and related molecular ion and base peak chemical 
structures. Image adapted from Baron et al (3). 
 
 
Figure 25. Mass spectrum of MDAI and related molecular ion and base peak chemical 
structures. Image adapted from Baron et al (3). 
The peaks m/z 242 for 5-IAI and m/z 160 for MDAI corresponds to a loss of 
amine (NH3) from the molecular ion. The formation of a distonic odd-electron 
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ion by the loss of NH3 [M-17] is a common fragment for diamines that undergo 
β-cleavage (59, 66). Typically, nitrogen has good electron donating capabilities 
that can initiate α-cleavage. Important fragments arise from α-cleavage of the 
carbon-carbon or carbon-hydrogen bond adjacent to the nitrogen (67). 
Although, this fragmentation loss of [M-17] would be considered uncommon in 
regards to amines, this fragmentation can occur because the 2, 3-dihydro-1H-
indene backbone structure can support the α-distonic ion that is formed (50, 
59, 66). The mechanism rearrangement for the ammonia loss in MDAI is shown 
in Figure 26. This mechanism is also believed to similar for the 5-IAI amine 
loss. 
 
 
Figure 26. Mechanism for the fragmentation loss of amine 
Preliminary analysis was done using MSD ChemStation G1701EA E.02.00.493 
software that was based on the calculated calibration curves. The linearity of 
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the response was confirmed in the range of concentrations that were described 
in the methods section. Preliminary analysis data is shown in Table 10 and are 
acceptable for the aminoindane compounds over the concentration range. 
 
Table 10. Preliminary analysis by GC-MS 
Compound Correlation 
Coefficient 
Relative Standard Deviation (%RSD)b 
1µg/ml 50µg/ml 100µg/ml 
5-IAI  0.9931 11.4 2.2 0.5 
MDAI 0.9968 18.1 5.2 1.0 
 
Determinations based on total ion chromatograms 
a Linearity range: 1-150µg/ml 
b Each value obtained from three determinations 
 
4.4.1 GC-MS Analysis of Mixtures 
With the current trends in synthetic designer drug products, the 
likelihood of encountering a sample with only one component is low. Many drug 
manufacturers seek to either complement the active ingredient(s) by adding 
adulterants or increase the bulk of the sample by the addition of diluents. 
Therefore, it is important to be able to detect multiple compounds within one 
sample for the purposes of proving or disproving allegations of clandestine drug 
syntheses or being a vendor of these substances (54). In order to determine if 
the GC-MS method was able to separate and detect mixtures, various multi-
component mixtures comprised of 5-IAI and MDAI and adulterants were 
assessed.  
“Street quality” mixtures were created with the aminoindane compounds 
and nine common adulterants. These samples were analyzed using the 
optimized GC-MS method. Figure 29 represents a chromatogram of a solution 
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containing equivalent 100µg/ml concentrations of the aminoindane compounds 
and the nine selected adulterants. Good separation of these compounds was 
achieved under the present conditions except for two components. It was 
identified that the target analyte 5-IAI and the adulterant acetaminophen had 
co-eluting peaks between the 6.00-6.30 min periods of the analysis. 
Due to the parameters of the GC-MS method used in this study, it is 
speculated that these particular compounds have similar affinities for the 
stationary phase. This resulted in co-elution when interpreting the TIC of this 
sample. Despite the co-elution of 5-IAI and acetaminophen, an extracted ion 
chromatogram was used to definitively identify the peaks in the solution. In 
addition, these compounds mass spectral data differed significantly which 
assisted with the identification of the co-eluting compounds.  
 
 
Figure 27. Representative chromatogram of a solution containing (A.)1-aminoindane, 
(B.)2-aminoindane, (C.)5,6-methylenedioxy-2-aminoindane, (D.)5-iodo-2-aminoindane, 
(1.)benzocaine, (2.)acetaminophen, (3.)m-CPP, (4.)caffeine, (5.)lidocaine, (6.)levamisole, 
(7.)procaine, (8.)dextromethorphan and (9.)metoclopramide. All components in mixture 
were at an equivalent concentration of 100µg/ml. 
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The method used allowed for improved peak separation between the two 
components but complete baseline resolution was not achieved (Figure 27). It 
can be difficult sometimes to achieve ideal chromatographic separation because 
of either the sample complexity or the chromatographic method employed. 
Therefore, even with the optimized experimental parameters, there is the 
possibility of co-elution during chromatographic separation with highly complex 
mixtures. While separation of mixtures by chromatography is important, this 
technique is typically used to provide qualitative information such as the 
retention time or determine the presence or absence of components when a 
standard is used (68). Quantification of co-eluting peaks may prove to be 
difficult if not followed by a spectroscopic technique such as MS, which adds a 
dimension of higher resolving power. Analyte concentration of co-eluting 
compounds can be determined with a SIM method that monitors specific m/z 
values and plots the ion current profile as a function of time (51, 59, 68). In 
addition, quantitative information can be obtained from ion abundances of 
mass spectral data for components that have a unique m/z value, in which 
calibration curves of ion abundance vs. concentration can be created and used 
for analysis of a component (68). 
Four additional contrived mixtures of “street quality” samples were 
analyzed using the AIN.M method. Analytes of interest varied between four 
concentrations (25µg/ml, 10µg/ml, 5µg/ml and 1µg/ml) while adulterant 
concentrations remained consistent at 100µg/ml. The target compounds were 
confirmed by GC-MS in the scan mode and quantitated in the SIM mode. Figure 
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30 represents a chromatogram that was based on the SIM acquisition data for 
5-IAI and MDAI at a concentration of 5µg/ml in a 13 component mixture. The 
M+ for each of these compounds were used as qualifier ions in which the SIM 
mode specifically targeted and measured during data acquisition. The potential 
internal standard compounds 1-AI and 2-AI in this figure are seen to have a 
greater abundance than 5-IAI and MDAI. This is due to the fact that these 
compounds share the same M+ value of m/z 133.0, which was used as the 
qualifier ion for these compounds. The peak for 1-AI and 2-AI in Figure 28 is 
the sum of both compounds contributing to the same ion current profile. The 
presence of other chromatographic peaks was seen in this data. The extraneous 
peaks are attributed to the adulterants in the compound that have either of the 
qualifier ions for 5-IAI or MDAI within their respective fragmentation pattern(s). 
SIM mode is designed to measure all abundances of the monitored ions, which 
is why these peaks are represented in the chromatogram of Figure 28. Figure 
29 and 30 represents the ion current profiles of 5-IAI and MDAI in the SIM 
mode. The presence of the extraneous peaks did not interfere with 
quantification of 5-IAI and MDAI because the ion current profiles are mapped 
as a function of time, which coincides with the elution period of the targeted 
compound. The M+ values that were measured during the SIM mode allowed for 
selective identification and quantification of the targeted compounds. The 
results for the preliminary analysis of 5-IAI and MDAI in the SIM mode were 
calculated using ChemStation software and presented in Table 11. This data is 
much more improved than data presented in Table 10 data for lower 
concentrations of 5-IAI and MDAI. . 
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Figure 28. Representative chromatogram of targeted analyte compounds based on 
acquired SIM data in a multi-component mixture. Mixture composed of 5µg/ml of 5-IAI 
and MDAI and 100 µg/ml of adulterants (n=3)  
 
 
Figure 29. 5-IAI mass spectral data based on acquired SIM data 
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Figure 30. MDAI mass spectral data based on acquired SIM data 
 
Table 11.Preliminary analysis of aminoindane analogues in the SIM 
mode using ChemStation software 
Compound Correlation 
Coefficient 
Relative Standard Deviation (%RSD)b 
1µg/ml 10µgl/ml 25µg/ml 
5-IAI  0.9908 4.9 3.9 20.1 
MDAI 0.9908 11.0 2.4 21.0 
Determinations based on total ion chromatograms 
a Linearity range: 1-25µg/ml 
b Each value obtained from three determinations 
 
The developed method proved capable of identifying and detecting all of the 
aminoindane compounds of interest. More importantly, this optimized method 
was able to identify and quantify the target compounds in a complex contrived 
mixture of selected adulterants at varying concentrations of analytes of interest. 
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5. Conclusions 
It is presently known that new designer drugs, commonly referred to as 
“legal highs” are frequently being manufactured by clandestine chemists. It is 
also known that these drugs are based on substitutions to the structure of the 
desired drug molecule. The compounds analyzed in this study, 5-IAI and MDAI 
are two examples of the derived substances that have appeared in the illicit 
drug market and proved difficult to identify since analytical data are not readily 
available for comparative purposes. Sensible techniques for the analysis of 5-IAI 
and MDAI were explored in an attempt to provide accurate characterization and 
possible quantification of these compounds. This research has shown that color 
tests, both NARK® II and In-House reagent systems are suitable methods for the 
preliminary identification of 5-IAI and MDAI. It was confirmed that four NARK® 
II tests reacted with 5-IAI to elicit a distinguishable color development, Marquis, 
Mecke, MDPV and Talwin reagents. Marquis reagent was the only test identified 
from the In-House colorimetric reagent preparations that had reacted with 5-IAI 
to elicit a color change. Six NARK® II tests were confirmed to elicit 
distinguishable color development for MDAI, Marquis, Mecke, Mandelin, MDPV, 
Nitric, and Talwin reagents. There were four In-House colorimetric preparations 
that were confirmed to elicit a color change for MDAI, Marquis, Mecke, 
Mandelin and Frohede reagents. Upon further investigation of the composition 
of the reagents that reacted with these compounds, it was found that most the 
reagents consisted of some combination of sulfuric acid (69). This is 
understandable as sulfuric acid is commonly used in a majority of colorimetric 
reagents and is known to foster a multitude of reactions (49). In the analysis of 
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“legal highs” with colorimetric reagents, it would prove useful to test the 
compound with a colorimetric reagent that contained sulfuric acid. The Marquis 
test was the most consistent test used in this study and generally is the first 
color test used in the analysis of unknown compound suspected of being an 
illegal substance. 5-IAI and MDAI reacted with Marquis reagent, producing an 
immediate brown and yellow-brown color formation, respectively.  
The following tests are commonly utilized by law enforcement for single 
use field test purposes: Froehde, Mandelin, Mecke, MDPV, Nitric and Talwin 
reagents. This study revealed that a number of color based reagent tests that 
are used in the law enforcement and forensic science communities, reacted with 
5-IAI and MDAI to elicit color development that can be used to presumptively 
identify trace amounts of 5-IAI and MDAI.  Further studies with color reagents 
revealed that the selected color reagents were sufficiently sensitive, rapid and 
displayed vivid colors, which would make it less likely to be mistaken for the 
reaction that is anticipated with the usual analyte of interest.  
 The consistency of the generated colors for 5-IAI and MDAI were 
assessed in the presence of several adulterants. It was determined that in an 
equivalent 1:1 ratio of mixed analyte of interest to adulterant in solution, the 
desired color development for the analyte of interest was visualized. However, it 
was determined that the amount of analyte can affect the intensity of the 
developed color as well as adulterants may interact with the colorimetric 
reagent formulations to form a nucleophilic compound. A nucleophilic 
compound would further react with the colorimetric reagents and partially 
inhibit the color development of the target compound. This would also manifest 
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in the loss of color intensity. Further research in this area would help to 
determine the effect of this on the color development. In the case of the MDAI 
and m-CPP mixture study, it was determined that the Mandelin reagent for 
both of the color reagent systems was able to indicate the presence of both 
compounds of the contrived mixture, with a green or green-brown color 
formation for MDAI and the development of a pink color indicating m-CPP.  
While it was determined that the In-House color reagent formulations 
recommended by the NIJ 0604.1 standard (55) were able to produce desirable 
results, they were not as effective or reliable when compared to the NARK® II 
reagents. In-House reagents were also determined to be not as sensitive as the 
NARK® II reagents. The desired color indicating 5-IAI and MDAI was hindered 
when in the presence of adulterants, more so than that of the NARK® II reagent 
tests. Narcotics identification systems such as NARK® II’s progressive 
identification system are designed to be rapid, robust and provide optimal color 
production, which is ideal for developing an analytical scheme for 
uncharacterized “legal highs.”  
This research has demonstrated the successful use of GC-MS for the 
analysis of 5-IAI and MDAI. A GC-MS analytical method was developed and 
optimized for the analysis of the indane-based compounds. A method was 
developed that is able to identify and quantify the target compounds in a 
complex contrived mixture of selected adulterants at varying concentrations of 
analytes of interest with use of the SIM mode parameter. It was also determined 
that 2-AI would serve as an ideal internal standard that would be used for the 
further development of a quantitative method. 5-IAI and MDAI are analogues of 
92 
 
2-AI and display similar chromatographic behaviors that are distinguishable 
from each other. If quantification of these target compounds are performed with 
a SIM based method then quantitative determination of the analyte would be 
based on a comparison of the ion current profile of the internal standard to the 
ion current profile of the targeted analyte within the given matrix (59). The 
AIN.M method was sufficiently sensitive to accurately quantify these 
compounds in a complex contrived mixture of selected adulterants at various 
concentrations. 
  
6. Future Directions 
Although the studies conducted herein have shown promise, more work 
could be done with colorimetric tests. One suggestion would be to research 
common adulterants that have been reported to have some form of color 
development with colorimetric tests. Multi-component mixtures would be 
created using 2-aminoindane analogues as the target analytes and 
incorporating any number of color producing adulterants. These mixtures 
would be tested with NARK® II and In-House colorimetric reagent preparations. 
The purpose of this would be to determine whether adulterants react with the 
colorimetric reagents and have the capacity to inhibit the color interpretation of 
the target analyte(s).   
Another suggested project would be to research various formulations of 
colorimetric tests aside from the NIJ standard recommendations. This inquiry 
would serve as a determination of what preparation would be the “best” for the 
identification of these 2-aminoindane analogues. Encountering another reagent 
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formulation could make the use of In-House reagents a cheaper and more 
viable approach than NARK® II reagent kits, without sacrificing the sensitivity 
and specificity for these compounds. The determination of the “best” reagent 
formulation would have to be conducted under a series of tests that would 
account for the amount of reagent used, time it took for color development, 
color intensity and amount analyte of used for a particular test. These are all 
important aspects for the optimization of a successful colorimetric test for 
screening purposes. An example of such an optimization method can be read in 
a 2012 Boston University graduate’s thesis work entitled “Development of 
Presumptive Macroscopic, Microscopic, and Colorimetric Tests for Salvia 
Divinorum, Salvinorin A, and Salvinorin B” by Keri L. LaBelle (70). The 
development of a validated method of analysis for emerging “legal highs” is of 
great importance to many forensic laboratories. An additional project that could 
be pursued is the validation of the AIN.M method for these aminoindane 
compounds. Currently, there are no published GC-MS methods that have been 
validated for the analysis of these aminoindane compounds. Validation of an 
analytical method incorporates many parameters such as accuracy, calibration 
models, carryover studies, interference studies, LOD, LOQ and precision (71). 
Validation studies would assess the efficacy and reliability of the AIN.M method 
for the analysis of 5-IAI and MDAI.  
 Another recommendation would be to employ other validated techniques 
in the analysis of 2-aminoindane analogues, such as FTIR analysis. This is 
another analytical technique that is commonly found in forensic laboratories. 
FTIR is used as a non-destructive measure of identifying unknown substances 
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and could be made applicable to the analysis of “legal highs”. Lastly, “legal 
high” products could be obtained from several Internet sites that are reported to 
contain 5-IAI and MDAI. The combination of colorimetric tests, GC-MS and 
FTIR analysis would provide valuable data regarding the chemical composition 
and quantitative information about these products. This would assist forensic 
chemists in determining whether “legal high” products that are sold over the 
Internet contain a combination of illegal substances/novel compounds or a 
mixture of adulterants as well as provide quantitative data.  
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